Accuray (ARAY) 10-K 29 Aug 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Jun. 30, 2014	Aug. 15, 2014	Dec. 31, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'ACCURAY INC	'	'
Entity Central Index Key	'0001138723	'	'
Document Type	'10-K	'	'
Document Period End Date	30-Jun-14	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--06-30	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$320,685,967
Entity Common Stock, Shares Outstanding	'	77,300,200	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$92,346	$73,313
Short-term investments	79,553	101,084
Restricted cash	1,492	2,728
Accounts receivable, net of allowance for doubtful accounts of $976 and $2,160, respectively	72,152	55,458
Inventories	87,752	81,592
Prepaid expenses and other current assets	17,873	12,595
Deferred cost of revenue	13,302	9,165
Total current assets	364,470	335,935
Property and equipment, net	34,391	34,733
Goodwill	58,091	59,368
Intangible assets, net	23,517	31,896
Deferred cost of revenue	2,899	2,149
Other assets	11,820	11,848
Total assets	495,188	475,929
Current liabilities:	'	'
Accounts payable	15,639	15,920
Accrued compensation	32,569	12,461
Other accrued liabilities	24,464	22,893
Customer advances	19,804	17,692
Deferred revenue	92,093	86,893
Total current liabilities	184,569	155,859
Long-term liabilities:	'	'
Long-term other liabilities	6,593	5,382
Deferred revenue	9,866	9,085
Long-term debt	195,612	198,768
Total liabilities	396,640	369,094
Commitment and contingencies (Note 5)	'	'
Stockholders' Equity:	'	'
Preferred stock, $0.001 par value; authorized: 5,000,000 shares; no shares issued and outstanding	'	'
Common stock, $0.001 par value; authorized: 200,000,000 shares as of June 30, 2014 and 2013 respectively; issued and outstanding: 77,178,365 and 74,587,231 shares at June 30, 2014 and 2013, respectively	77	75
Additional paid-in capital	451,750	424,524
Accumulated other comprehensive income	1,815	1,882
Accumulated deficit	-355,094	-319,646
Total stockholders' equity	98,548	106,835
Total liabilities and stockholders' equity	$495,188	$475,929

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, except Share data, unless otherwise specified
Consolidated Balance Sheets	'	'
Accounts receivable, allowance for doubtful accounts (in dollars)	$976	$2,160
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, authorized shares	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized shares	200,000,000	200,000,000
Common stock, issued shares	77,178,365	74,587,231
Common stock, outstanding shares	77,178,365	74,587,231

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Net revenue:	'	'	'
Products	$173,607	$137,403	$240,472
Services	195,812	178,571	168,751
Total net revenue	369,419	315,974	409,223
Cost of revenue:	'	'	'
Cost of products	97,592	85,498	136,180
Cost of services	129,027	132,836	135,771
Total cost of revenue	226,619	218,334	271,951
Gross profit	142,800	97,640	137,272
Operating expenses:	'	'	'
Research and development	53,724	66,197	81,287
Selling and marketing	61,885	54,372	54,547
General and administrative	45,335	57,726	57,672
Total operating expenses	160,944	178,295	193,506
Loss from operations	-18,144	-80,655	-56,234
Other expense, net	-14,216	-13,133	-12,521
Loss before provision for income taxes	-32,360	-93,788	-68,755
Provision for income taxes	3,088	3,573	2,595
Loss from continuing operations	-35,448	-97,361	-71,350
Loss from discontinued operations:	'	'	'
Loss from operations of a discontinued variable interest entity	'	-3,505	-7,103
Impairment of indefinite lived intangible asset of discontinued variable interest entity	'	-12,200	'
Loss from deconsolidation of a variable interest entity	'	-3,442	'
Loss from discontinued operations, net of tax of $0	'	-19,147	-7,103
Loss from discontinued operations attributable to non-controlling interest	'	-13,289	-6,411
Loss from discontinued operations attributable to stockholders	'	-5,858	-692
Net loss attributable to stockholders	-35,448	-103,219	-72,042
Loss per share attributable to stockholders	'	'	'
Basic and diluted - continuing operations (in dollars per share)	($0.47)	($1.33)	($1.01)
Basic and diluted - discontinued operations (in dollars per share)	'	($0.08)	($0.01)
Basic and diluted - net loss (in dollars per share)	($0.47)	($1.41)	($1.02)
Weighted average common shares used in computing loss per share	'	'	'
Basic and diluted (in shares)	75,804	73,281	70,887
Net loss attributable to stockholders	-35,448	-103,219	-72,042
Foreign currency translation adjustment	25	-498	2,710
Unrealized gain (loss) on investments	475	-457	'
Defined benefit pension obligation	-567	'	'
Comprehensive loss	($35,515)	($104,174)	($69,332)

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2012
Consolidated Statements of Operations and Comprehensive Loss	'	'
Loss from discontinued operations, tax	$0	$0

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Total Stockholders' Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Non-controlling Interest
In Thousands, except Share data, unless otherwise specified
Balance at Jun. 30, 2011	$240,327	$229,775	$70	$373,963	$127	($144,385)	$10,552
Balance (in shares) at Jun. 30, 2011	'	'	70,059,819	'	'	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'	'	'
Exercise of stock options, net	1,866	1,866	1	1,865	'	'	'
Exercise of stock options, net (in shares)	'	'	746,441	'	'	'	'
Issuance of restricted stock (in shares)	'	'	302,476	'	'	'	'
Issuance of common stock under employee stock purchase plan	2,581	2,581	1	2,580	'	'	'
Issuance of common stock under employee stock purchase plan (in shares)	'	'	755,532	'	'	'	'
Share-based compensation	7,546	7,546	'	7,546	'	'	'
Equity conversion component from issuance of convertible notes	23,189	23,189	'	23,189	'	'	'
Change in non-controlling interest in CPAC	4,101	'	'	'	'	'	4,101
Net income from noncontrolling interest	-6,411	'	'	'	'	'	'
Net loss	-72,042	-72,042	'	'	'	-72,042	-6,411
Cumulative translation adjustment	2,710	2,710	'	'	2,710	'	'
Balance at Jun. 30, 2012	203,867	195,625	72	409,143	2,837	-216,427	8,242
Balance (in shares) at Jun. 30, 2012	'	'	71,864,268	'	'	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'	'	'
Exercise of stock options, net	4,201	4,201	2	4,199	'	'	'
Exercise of stock options, net (in shares)	'	'	1,514,591	'	'	'	'
Issuance of restricted stock (in shares)	'	'	544,386	'	'	'	'
Issuance of common stock under employee stock purchase plan	3,257	3,257	1	3,256	'	'	'
Issuance of common stock under employee stock purchase plan (in shares)	'	'	663,986	'	'	'	'
Share-based compensation	8,236	8,236	'	8,236	'	'	'
Deconsolidation of CPAC	4,737	-310	'	-310	'	'	5,047
Net income from noncontrolling interest	-13,289	'	'	'	'	'	'
Net loss	-103,219	-103,219	'	'	'	-103,219	-13,289
Cumulative translation adjustment	-498	-498	'	'	-498	'	'
Unrealized gain (loss) on investments, net of tax	-457	-457	'	'	-457	'	'
Balance at Jun. 30, 2013	106,835	106,835	75	424,524	1,882	-319,646	'
Balance (in shares) at Jun. 30, 2013	74,587,231	'	74,587,231	'	'	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'	'	'
Exercise of stock options, net	5,312	5,312	1	5,311	'	'	'
Exercise of stock options, net (in shares)	'	'	1,061,513	'	'	'	'
Issuance of restricted stock	1	1	1	'	'	'	'
Issuance of restricted stock (in shares)	'	'	913,070	'	'	'	'
Issuance of common stock under employee stock purchase plan	3,536	3,536	'	3,536	'	'	'
Issuance of common stock under employee stock purchase plan (in shares)	'	'	650,315	'	'	'	'
Share-based compensation	11,038	11,038	'	11,038	'	'	'
Equity conversion component from issuance of convertible notes	7,844	7,844	'	7,844	'	'	'
Unamortized convertible senior note issuance costs reclassified to equity in relation to convertible notes modification	-243	-243	'	-243	'	'	'
Tax withholding upon vesting of restricted stock awards	-260	-260	'	-260	'	'	'
Taxwithholding upon vesting of restricted stock awards (in shares)	'	'	-33,764	'	'	'	'
Net loss	-35,448	-35,448	'	'	'	-35,448	'
Cumulative translation adjustment	25	25	'	'	25	'	'
Unrealized gain (loss) on investments, net of tax	475	475	'	'	475	'	'
Defined benefit pension obligation	-567	-567	'	'	-567	'	'
Balance at Jun. 30, 2014	$98,548	$98,548	$77	$451,750	$1,815	($355,094)	'
Balance (in shares) at Jun. 30, 2014	77,178,365	'	77,178,365	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Cash Flows From Operating Activities	'	'	'
Loss from continuing operations	($35,448)	($97,361)	($71,350)
Loss from discontinued operations	'	-19,147	-7,103
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'	'	'
Depreciation and amortization	20,564	25,564	32,592
Impairment of indefinite lived intangible asset	'	12,200	'
Share-based compensation	11,313	8,216	8,458
Amortization of debt issuance costs	1,408	784	363
Accretion/(amortization) of investment premiums/discounts	1,584	295	'
Accretion of interest on long-term debt	5,105	4,302	3,596
Provision for bad debt	-707	787	1,392
Provision for write-down of inventories	2,836	5,255	2,129
Loss on disposal of property and equipment	666	1,013	296
Gain on previously held equity interest in Morphormics	'	-662	'
Loss from deconsolidation of a variable interest entity	'	3,442	'
Provision for deferred income taxes	92	947	495
Changes in assets and liabilities:	'	'	'
Restricted cash	-163	-1,163	1,605
Accounts receivable	-14,786	10,858	-9,162
Inventories	-8,341	-5,147	11,927
Prepaid expenses and other assets	-5,241	4,382	2,523
Deferred cost of revenue	-4,875	-4,005	2,080
Accounts payable	-1,057	-1,140	-21,425
Accrued liabilities	21,696	-18,525	-10,538
Customer advances	1,744	-659	-7,044
Deferred revenue	3,956	3,587	20,887
Net cash provided by (used in) operating activities	346	-66,177	-38,279
Cash Flows From Investing Activities	'	'	'
Purchases of property and equipment, net	-11,931	-15,126	-10,769
Purchases of intangible assets	'	-232	'
Purchases of investments	-44,155	-102,403	'
Sales and maturities of investments	64,578	'	'
Acquisition of business, net of cash acquired	'	-3,861	-1,384
Net cash provided by (used in) investing activities	8,492	-121,622	-12,153
Cash Flows From Financing Activities	'	'	'
Proceeds from issuance of common stock	9,054	7,455	4,449
Payment to the convertible note holders to modify the notes	-417	'	'
Taxes paid related to net share settlement of equity awards	-260	'	'
Proceeds from debt, net of costs	'	110,462	96,100
Net cash provided by financing activities	8,377	117,917	100,549
Effect of exchange rate changes on cash and cash equivalents	1,818	-309	-2,519
Net increase (decrease) in cash and cash equivalent	19,033	-70,191	47,598
Cash and cash equivalents at beginning of period	73,313	143,504	95,906
Cash and cash equivalents at end of period	92,346	73,313	143,504
Supplemental Disclosure of Cash Flow Information	'	'	'
Cash paid for income taxes	2,499	2,000	1,198
Cash paid for interest	8,208	3,750	1,875
Non-cash financing activity:	'	'	'
Carrying amount of the equity conversion component	7,844	'	23,189
Purchases of property and equipment recorded in accounts payable and accrued liabilities	$1,142	$366	$389

Description_of_Business

Description of Business	12 Months Ended
	Jun. 30, 2014
Description of Business	'
Description of Business	'
	1. Description of Business
	Organization
	Accuray Incorporated (together with its subsidiaries, the "Company" or "Accuray") is incorporated in Delaware. The Company designs, develops and sells advanced radiosurgery and radiation therapy systems for the treatment of tumors throughout the body. The Company conducts its business worldwide. The Company has its headquarters in Sunnyvale, California, with additional locations worldwide.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Basis of Presentation and Principles of Consolidation
	The accompanying consolidated financial statements have been prepared in accordance with GAAP, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. The consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries and a variable interest entity, Compact Particle Acceleration Corporation, or CPAC until the deconsolidation of CPAC on December 21, 2012 (for further information, see Note 7, Investment in CPAC). All significant inter-company transactions and balances have been eliminated in consolidation.
	Discontinued Operations
	As a result of the deconsolidation of CPAC, the results of operations of CPAC, including the loss on deconsolidation of CPAC and the losses attributable to the non-controlling interest recorded for the years ended June 30, 2013 and 2012 have been presented as discontinued operations.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures at the date of the financial statements. Key estimates and assumptions made by the Company relate to revenue recognition, business combinations and assessment of recoverability of goodwill and intangible assets, valuation of inventories, share-based compensation expense, convertible notes, income taxes, allowance for doubtful accounts and loss contingencies. Actual results could differ materially from those estimates.
	Foreign Currency
	The Company's international subsidiaries use their local currencies as their functional currencies. For those subsidiaries, assets and liabilities are translated at exchange rates in effect at the balance sheet date and income and expense accounts at the average exchange rate. Resulting translation adjustments are excluded from the determination of net income (loss) and are recorded in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Net foreign currency exchange transaction gains or losses are included as a component of other income (expense), net, in the Company's consolidated statements of operations and comprehensive loss.
	Fair Value Measurements
	The carrying values of the Company's financial instruments including cash equivalents, restricted cash, accounts receivable and accounts payable are approximately equal to their respective fair values due to the relatively short-term nature of these instruments. Also refer to Note 4, Financial Instruments, for further details.
	Cash and Cash Equivalents
	The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are held in various financial institutions in the United States and internationally.
	Investments
	The Company classifies all its investments as available-for-sale at the time of purchase since it is management's intent that these investments be available for current operations, and as such, includes these investments as short-term investments on its balance sheets. These investments consist of fixed-term deposits, commercial paper and investment-grade corporate debt securities with original maturities longer than three months. Short-term investments classified as available-for-sale are recorded at fair market value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders' equity. Realized gains and losses are recorded in the consolidated statements of operations and comprehensive loss based on specific identification.
	Concentration of Credit Risk and Other Risks and Uncertainties
	The Company's cash and cash equivalents are mainly deposited with several major financial institutions. At times, deposits in these institutions exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances. The Company has placed its investments with high-credit quality issuers. The Company does not invest an amount exceeding 5% of its combined cash, cash equivalents and investments in the securities of any one obligor or maker, except for obligations of the United States government, obligations of United States government agencies and money market accounts.
	There were no customers that represented 10% or more of total net revenue for the years ended June 30, 2014, 2013 and 2012. At June 30, 2014, one customer accounted for 13% of accounts receivable. At June 30, 2013, one customer accounted for 10% of accounts receivable.
	Accounts receivable are typically not collateralized. The Company performs ongoing credit evaluations of its customers and maintains reserves for potential credit losses. Accounts receivable are deemed past due in accordance with the contractual terms of the agreement. Accounts are charged against the allowance for doubtful accounts once collection efforts are unsuccessful. Historically, such losses have been within management's expectations.
	Single-source suppliers presently provide the Company with several components. In most cases, if a supplier was unable to deliver these components, the Company believes that it would be able to find other sources for these components subject to any regulatory qualifications, if required.
	Restricted Cash
	Restricted cash primarily consists of certificates of deposit held as guarantees in connection with corporate leases as well as funds held as guarantees for Value-Added Tax, or VAT obligations in a foreign jurisdiction.
	Inventories
	Inventories are stated at the lower of cost (on a first-in, first-out basis) or market value. Excess and obsolete inventories are written down based on historical sales and forecasted demand, as judged by management. The Company determines inventory and product costs, which include allocated production overheads, through use of standard costs, which approximate actual costs.
	Revenue Recognition
	The Company's revenue is primarily derived from sales of CyberKnife and TomoTherapy Systems and services, which include post-contract customer support or PCS, installation services, training and other professional services. The Company records its revenues net of any value added or sales tax. In all sales arrangements, the Company recognizes revenues when there is persuasive evidence of an arrangement, the fee is fixed or determinable, collection of the fee is reasonably assured and delivery has occurred. Payments received in advance of system shipment are recorded as customer advances and are recognized as revenue or deferred revenue upon product shipment or installation. The Company assesses the probability of collection based on a number of factors, including past transaction history with the customer and the credit-worthiness of the customer. The Company generally does not request collateral from its customers. If the Company determines that collection is not probable, the Company will defer the fee and recognize revenue upon receipt of cash.
	The Company frequently enters into sales arrangements that contain multiple elements or deliverables. For sale arrangements that contain multiple elements, the Company allocates the arrangement consideration to each element based on the relative selling price method, whereby the relative selling price of each deliverable is determined using vendor specific objective evidence, or VSOE of fair value, if it exists. VSOE of fair value for each element is based on the Company's standard rates charged for the product or service when such product or service is sold separately or based upon the price established by the Company's pricing committee when that product or service is not yet being sold separately. When the Company is not able to establish VSOE for all deliverables in an arrangement with multiple elements, which may be due to the Company infrequently selling each element separately, not pricing products within a narrow range, or only having a limited sales history, the Company attempts to determine the selling price of each element based on third-party evidence of selling price, or TPE, as determined based on competitors' prices for similar deliverables when sold separately. When the Company is not able to establish selling price using VSOE or TPE, the Company uses its best estimate of selling price, or BESP, in its allocation of arrangement consideration. The objective of BESP is to determine the price at which the Company would transact a sale if the product or service were sold on a stand-alone basis. The Company determines BESP for a product or service by considering multiple factors including, but not limited to, pricing practices, internal costs, geographies and gross margin. The determination of BESP is made through consultation with the Company's pricing committee, taking into consideration its overall go-to-market pricing strategy.
	The Company has a limited number of software offerings which are not required to deliver its systems' essential functionality and can be sold separately. The Company accounts for the separate sale of its software products in accordance with the applicable guidance for software revenue recognition. The Company's multiple-element arrangements may also include software deliverables that are subject to the software revenue recognition guidance; and in these cases, the revenue for these multiple-element arrangements is allocated to the software deliverable and the non-software deliverables based on the relative selling prices of all of the deliverables in the arrangement using VSOE, TPE or BESP.
	The Company regularly reviews VSOE, TPE and BESP for all of its products and services. As the Company's go-to-market strategies and other factors change, the Company may modify its pricing practices in the future, which may impact the selling prices of systems and services as well as VSOE, TPE and BESP of systems and services. As a result, the Company's future revenue recognition for multiple element arrangements could differ materially from that recorded in the current period.
	Product Revenue
	The majority of product revenue is generated from sales of CyberKnife and TomoTherapy systems. If the Company is responsible for installation, the Company recognizes revenue after installation and acceptance of the system. Otherwise, revenue is recognized upon delivery, assuming all other revenue recognition criteria are met.
	The Company could sell its systems with PCS contracts, installation services, training, and at times, professional services. PCS contracts provide planned and corrective maintenance services, software updates, bug fixes, as well as call-center support.
	The Company records revenues from sales of systems, product upgrades and accessories to distributors depending on the terms of the distribution agreement as well as terms and conditions executed for each sale, and once all revenue recognition criteria have been met.
	The Company's agreements with customers and distributors for system sales generally do not contain product return rights. Certain distributor agreements include parts inventory buy-back provisions upon distributorship termination. The Company accrues an inventory buy-back liability when and if such distributorship termination is expected and the liability can be estimated.
	Service Revenue
	Service revenue is generated primarily from PCS (warranty period services and post warranty services), installation services, training, and professional services. PCS revenue is deferred and recognized over the service period. Installation service revenue is recognized concurrent with system revenue. Training revenues are recognized when services are performed, and professional service revenues that are not deemed essential to the functionality of the systems are recognized as such services are performed.
	Costs associated with service revenue are expensed when incurred, except when those costs are related to system upgrades where revenue recognition has been deferred. In those cases, the incremental costs are deferred and are recognized over the period of revenue recognition.
	Deferred Revenue and Deferred Cost of Revenue
	Deferred revenue consists of deferred product revenue and deferred service revenue. Deferred product revenue arises from timing differences between the shipment of product and satisfaction of all revenue recognition criteria consistent with the Company's revenue recognition policy. Deferred service revenue results from the advance payment for services to be delivered over a period of time, usually one year. Deferred cost of revenue consists of the direct costs associated with the manufacturing of units and direct service costs for which the revenue has been deferred in accordance with the Company's revenue recognition policies. Deferred revenue and associated deferred cost of revenue expected to be realized within one year are classified as current liabilities and current assets, respectively.
	Customer Advances
	Customer advances represent payments made by customers in advance of product shipment.
	Property and Equipment
	Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are depreciated on a straight-line basis over the remaining term of the lease or the estimated useful life of the asset, whichever is shorter. Machinery and equipment are depreciated over five years. Furniture and fixtures are depreciated over four years. Computer and office equipment and computer software are depreciated over three years. Repairs and maintenance costs, which are not considered improvements and do not extend the useful life of the property and equipment, are expensed as incurred.
	Software Capitalization Costs
	The Company capitalizes certain costs associated with obtaining or developing internal use software, including external direct costs of material and services. Software development costs relating to assets to be sold in the normal course of business are included in research and development and are expensed as incurred until technological feasibility is established. After technological feasibility is established, material software development costs are capitalized. The capitalized cost is then amortized on a straight-line basis over the estimated product life, or on the ratio of current revenues to total projected product revenue, whichever is greater. To date, the period between achieving technological feasibility, which the Company has defined as the establishment of a working model which typically occurs when the beta testing commences, and the general availability of such software has been short and software development costs qualifying for capitalization have been insignificant.
	Capitalized software costs are included in property, plant and equipment and amortized beginning when the software project is complete and the assets is ready for its intended use.
	Impairment of Long-Lived Assets
	The Company reviews long-lived assets, including intangible assets, property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable using pretax undiscounted cash flows. Impairment, if any, is measured as the amount by which the carrying value of a long-lived asset exceeds its fair value.
	Business Combinations
	The Company allocates the fair value of the purchase consideration of its acquisitions to the tangible assets, liabilities, and intangible assets acquired, including in-process research and development, or IPR&D, based on their estimated fair values. Goodwill represents the excess of acquisition cost over the fair value of tangible and identified intangible net assets of businesses acquired. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired company are reflected in the Company's consolidated financial statements after the closing date of the merger or acquisition.
	Goodwill and Purchased Intangible Assets
	Goodwill is not amortized, but is evaluated for impairment on an annual basis and when impairment indicators are present. The Company has assessed that it has one operating segment and one reporting unit, and the consolidated net assets, including existing goodwill and other intangible assets, are considered to be the carrying value of the reporting unit. The Company estimates the fair value of the reporting unit based on the Company's closing stock price on the trading day closest to the annual review date multiplied by the outstanding shares on that date. If the carrying value of the reporting unit is in excess of its fair value, an impairment may exist, and the Company must perform the second step of the analysis, in which the implied fair value of the goodwill is compared to its carrying value to determine the impairment charge, if any. If the estimated fair value of the reporting unit exceeds the carrying value of the reporting unit, goodwill is not impaired and no further analysis is required. There was no impairment of goodwill identified in the fiscal years ended June 30, 2014, 2013 and 2012.
	Purchased intangible assets other than goodwill, including developed technology, backlog and distributor license, are amortized on a straight-line basis over their estimated useful lives unless their lives are determined to be indefinite. Purchased intangible assets are carried at cost, less accumulated amortization. Amortization is computed over the estimated useful lives of the respective assets which range from approximately one to six years.
	Acquisition-related expenses and restructuring costs are recognized separately from the business combination and are expensed as incurred.
	Shipping and Handling
	The Company's billings for shipping and handling for product shipments to customers are included in cost of products. Shipping and handling costs incurred for inventory purchases are capitalized in inventory and expensed in cost of products.
	Advertising Expenses
	The Company expenses the costs of advertising and promoting its products and services as incurred. Advertising expenses were approximately $0.6 million, $0.7 million and $0.5 million for the years ended June 30, 2014, 2013 and 2012, respectively.
	Research and Development Costs
	Costs related to research, design and development of products are charged to research and development expense as incurred. These costs include direct salaries, benefits, and other headcount related costs for research and development personnel; costs for materials used in research and development activities; costs for outside services and allocated portions of facilities and other corporate costs. The Company has entered into research and clinical study arrangements with selected hospitals, cancer treatment centers, academic institutions and research institutions worldwide. These agreements support the Company's internal research and development capabilities.
	Share-Based Compensation
	The Company issues stock-based compensation awards to employees and directors in the form of stock options, restricted stock units ("RSUs"), performance stock units ("PSUs"), market stock units ("MSUs") and employee stock purchase plan ("ESPP") awards (collectively, "awards").
	The Company measures and recognizes compensation expense for all stock-based awards based on the awards' fair value. Share-based compensation for RSUs and PSUs is measured based on the value of the Company's common stock on the grant date. The Company uses the Monte-Carlo simulation model to estimate the fair value of MSUs. Share-based compensation for employee stock options and ESPP awards are measured on the date of grant using a Black-Scholes option pricing model.
Awards vest either on a graded schedule or in a lump sum. The Company determines the fair value of each award as a single award and recognizes the expense on a straight-line basis over the service period of the award, which is generally the vesting period. The exercise price of stock options granted is equal to the fair market value of the Company's common stock on the date of grant. Stock options expire ten years from the date of grant.
Share-based compensation expense for stock options, RSUs, PSUs and the ESPP is based on awards ultimately expected to vest, and the expense is recorded net of estimated forfeitures. The Company recognizes expense for MSUs net of estimated forfeitures and does not adjust the expense for subsequent changes in the expected outcome of the market-based vesting conditions.
Loss Contingencies
The Company is involved in various lawsuits, claims and proceedings that arise in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. The Company reviews these provisions at least quarterly and adjusts these provisions to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, and updated information.
Net Loss Per Common Share
Basic and diluted net loss per share is computed by dividing net loss attributable to stockholders by the weighted average number of common shares outstanding during the year.
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to stockholders follows (in thousands):
	Years ended June 30,
	2014			2013			2012
Numerator:
Loss from operations used in computing loss per share from continuing operations	$	(35,448	)	$	(97,361	)	$	(71,350	)
Loss from discontinued operations used in computing loss per share from discontinued operations		—		$	(5,858	)	$	(692	)
Net loss used in computing net loss per share	$	(35,448	)	$	(103,219	)	$	(72,042	)
Denominator:
Weighted average shares used in computing basic and diluted net loss per share		75,804			73,281			70,887
The potentially dilutive shares of the Company's common stock resulting from the assumed exercise of outstanding stock options, the vesting of RSUs, MSUs and PSUs, and the purchase of shares under the ESPP, as determined under the treasury stock method, are excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive. The 3.75% Convertible Senior Notes due August 1, 2016 (the "3.75% Convertible Notes"), the 3.50% Convertible Senior Notes due February 1, 2018 (the "3.50% Convertible Notes") and the 3.50% Series A Convertible Notes (the "3.50% Series A Convertible Notes") due February 1, 2018 are included in the calculation of diluted net income per share only if their inclusion is dilutive. For the years ended June 30, 2014, 2013 and 2012, the potentially dilutive shares under the Convertible Notes were excluded from the calculation of diluted net loss per share as their inclusion would have been anti-dilutive. The following table sets forth all potentially dilutive securities excluded from the computation in the table above because their effect would have been anti-dilutive (in thousands):
	As of June 30,
	2014			2013			2012
Stock options		3,209			4,844			7,873
RSUs, PSUs and MSUs		3,947			3,387			2,097
3.75% Convertible Notes		—			—			—
3.50% Convertible Notes		8,378			21,576			—
3.50% Series A Convertible Notes		4,985			—			—
		20,519			29,807			9,970
Outstanding Convertibles Notes—Diluted Share Impact
The 3.75% Convertible Notes and 3.50% Series A Convertible Notes have an optional physical (share), cash or combination settlement feature and contain certain conditional conversion features. Due to the optional cash settlement feature and management's intent to settle the principal amount thereof in cash, the conversion shares underlying the outstanding principal amount of the 3.75% Convertible Notes and 3.50% Series A Convertible Notes, totaling approximately 10.6 million shares and 13.2 million shares, respectively, were not included in the potentially diluted share count table above. The Company's average stock price did not exceed the conversion price of the 3.75% Convertible Notes as of June 30, 2014, 2013 and 2012. The 5.0 million potentially dilutive shares of the 3.50% Series A Convertible Notes included in the table above represent the premium over the principal amount due to the higher average share price. The number of premium shares included in the Company's diluted share count will vary with fluctuations in the Company's share price. Higher actual share prices result in a greater number of premium shares.
Income Taxes
The Company is required to estimate its income taxes in each of the tax jurisdictions in which it operates prior to the completion and filing of tax returns for such periods. This process involves estimating actual current tax expense together with assessing temporary differences in the treatment of items for tax purposes versus financial accounting purposes that may create net deferred tax assets and liabilities. The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of the Company's assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses, research and development credit carryforwards, and other deferred tax assets.
The Company records a valuation allowance to reduce its deferred tax assets to the amount the Company believes is more likely than not to be realized. Because of the uncertainty of the realization of the deferred tax assets, the Company has recorded a full valuation allowance against its domestic and certain foreign net deferred tax assets.
The calculation of unrecognized tax benefits involves dealing with uncertainties in the application of complex global tax regulations. Management regularly assesses the Company's tax positions in light of legislative, bilateral tax treaty, regulatory and judicial developments in the countries in which the Company does business. The Company anticipates that except for $0.3 million in uncertain tax positions that may be reduced related to the lapse of various statutes of limitation, there will be no material changes in uncertain tax positions in the next 12 months.
Accumulated Other Comprehensive Income
The components of comprehensive loss consist of net loss, unrealized gains and losses on available-for-sale investments, changes in foreign currency exchange rate translation and net changes related to defined benefit pension plan. The unrealized gains and losses on available-for-sale investments, changes in foreign currency exchange rate translation and net changes related to defined benefit pension plan are excluded from earnings and reported as a component of stockholders' equity. The foreign currency translation adjustment results from those subsidiaries not using the United States dollar as their functional currency since the majority of their economic activities are primarily denominated in their applicable local currency. Accordingly, all assets and liabilities related to these operations are translated at the current exchange rates at the end of each period. The resulting cumulative translation adjustments are recorded directly to the accumulated other comprehensive loss account in stockholders' equity. Revenues and expenses are translated at average exchange rates in effect during the period.
The components of accumulated other comprehensive income in the equity section of the balance sheets are as follows (in thousands):
	June 30,			June 30,
	2014			2013
Net unrealized gain (loss) on short-term investments	$	18		$	(457	)
Cumulative foreign currency translation gain		2,364			2,339
Change in defined benefit pension obligation		(567	)		—
Accumulated other comprehensive income	$	1,815		$	1,882
Segment Information
The Company has determined that it operates in only one segment, as it only reports profit and loss information on an aggregate basis to its chief operating decision maker. Revenue by geographic region is based on the shipping addresses of the Company's customers. The following summarizes revenue by geographic region (in thousands):
	Years ended June 30,
	2014			2013			2012
Americas	$	156,242		$	143,613		$	189,072
Europe, Middle East, India and Africa		115,396			101,172			110,331
Asia (excluding Japan and India)		44,533			37,829			64,026
Japan		53,248			33,360			45,794
Total	$	369,419		$	315,974		$	409,223
Information regarding geographic areas in which the Company has long lived tangible assets is as follows (in thousands):
	June 30,			June 30,
	2014			2013
Americas	$	30,542		$	31,797
Europe, Middle East, India and Africa		1,665			1,431
Asia (excluding Japan and India)		444			498
Japan		1,740			1,007
Total	$	34,391		$	34,733
Recent Accounting Pronouncements
In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company in its first quarter of fiscal 2018 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09. The Company is currently evaluating the impact of pending adoption of ASU 2014-09 on its consolidated financial statements.
In July 2013, the Financial Accounting Standards Board ("FASB") issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU No. 2013-11 requires that entities with an unrecognized tax benefit and a net operating loss carryforward or similar tax loss or tax credit carryforward in the same jurisdiction as the uncertain tax position present the unrecognized tax benefit as a reduction of the deferred tax asset for the loss or tax credit carryforward rather than as a liability, when the uncertain tax position would reduce the loss or tax credit carryforward under the tax law, thereby eliminating diversity in practice regarding this presentation issue. This new guidance is effective prospectively for annual reporting periods beginning on or after December 15, 2013, although retrospective application is permitted. The Company is currently assessing the impact of this guidance, if any, on its consolidated financial statements.
In March 2013, the FASB issued ASU No. 2013-05, Foreign Currency Matters (Topic 830): Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. This new standard is intended to resolve diversity in practice regarding the release into net income of a cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. ASU No. 2013-05 is effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013. The Company is currently reviewing this standard, but it does not anticipate that its adoption will have a material impact on the Company's consolidated financial statements.

Balance_Sheet_Components

Balance Sheet Components	12 Months Ended
	Jun. 30, 2014
Balance Sheet Components	'
Balance Sheet Components	'
	3. Balance Sheet Components
	Cash and Cash Equivalents
	The following is a summary of cash and cash equivalents (in thousands):
		June 30,			June 30,
		2014			2013
	Cash	$	91,797		$	60,082
	Certificates of deposit		—			12,758
	Money market funds		549			473
		$	92,346		$	73,313
	Accounts receivable, net
	Accounts receivable, net consisted of the following (in thousands):
		June 30,			June 30,
		2014			2013
	Accounts receivable	$	72,969		$	56,830
	Unbilled fees and services		159			788
			73,128			57,618
	Less: Allowance for doubtful accounts		(976	)		(2,160	)
	Accounts receivable, net	$	72,152		$	55,458
	The Company deducted $0.7 million and added $0.8 million, and wrote off $0.5 million and $0.3 million from the allowance for doubtful accounts in fiscal 2014 and 2013, respectively.
	Financing receivables
	A financing receivable is a contractual right to receive money, on demand or on fixed or determinable dates, that is recognized as an asset in the Company's balance sheet. The Company's financing receivables, consisting of its accounts receivable with contractual maturities of more than one year totaled $2.8 million and $2.9 million at June 30, 2014 and 2013, respectively and are included in Other Assets in the consolidated balance sheets. There was no balance in the allowance for doubtful accounts related to such financing receivables as of June 30, 2014 and June 30, 2013, respectively; revenue is recognized on a cash basis for these receivables.
	Inventories
	Inventories consisted of the following (in thousands):
		June 30,			June 30,
		2014			2013
	Raw materials	$	37,003		$	33,721
	Work-in-process		17,692			20,564
	Finished goods		33,057			27,307
	Inventories	$	87,752		$	81,592
	Property and Equipment, net
	Property and equipment consisted of the following (in thousands):
		June 30,			June 30,
		2014			2013
	Furniture and fixtures	$	5,351		$	6,506
	Computer and office equipment		10,540			9,481
	Software		10,736			9,586
	Leasehold improvements		18,991			19,199
	Machinery and equipment		39,465			37,371
	Shared ownership systems		6,265			4,979
	Construction in progress		5,877			3,084
			97,225			90,206
	Less: Accumulated depreciation		(62,834	)		(55,473	)
	Property and equipment, net	$	34,391		$	34,733
	Depreciation and amortization expense related to property and equipment for the years ended June 30, 2014, 2013 and 2012 was $12.2 million, $15.2 million and $16.4 million, respectively.

Financial_Instruments

Financial Instruments	12 Months Ended
	Jun. 30, 2014
Financial Instruments	'
Financial Instruments	'
	4. Financial Instruments
	The Company considers all highly liquid investments held at major banks, certificates of deposit and other securities with original maturities of three months or less to be cash equivalents.
	The Company classifies all of its investments as available-for-sale at the time of purchase because it is management's intent that these investments are available for current operations and includes these investments on its balance sheets as short-term investments. Investments with original maturities longer than three months include commercial paper and investment-grade corporate debt securities. Investments classified as available-for-sale are recorded at fair market value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders' equity. Realized gains and losses are recorded based on specific identification of each security's cost basis.
	The Company defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy contains three levels of inputs that may be used to measure fair value, as follows:
	Level 1—Unadjusted quoted prices that are available in active markets for the identical assets or liabilities at the measurement date.
	Level 2—Other observable inputs available at the measurement date, other than quoted prices included in Level 1, either directly or indirectly, including:
	•
	Quoted prices for similar assets or liabilities in active markets;
	•
	Quoted prices for identical or similar assets in non-active markets;
	•
	Inputs other than quoted prices that are observable for the asset or liability; and
	•
	Inputs that are derived principally from or corroborated by other observable market data.
	Level 3—Unobservable inputs that cannot be corroborated by observable market data and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management's estimates of market participant assumptions.
	The following tables summarize the amortized cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category for cash, cash equivalents and short-term investments (in thousands):
		June 30, 2014
									Estimated Market Value
		Amortized		Gross		Gross			Cash and Cash		Short-term
		Cost		Unrealized		Unrealized			Equivalents		Investments
				Gains		Losses
	Cash	$	91,797	$	—	$	—		$	91,797	$	—
	Level 1
	Money market funds		549		—		—			549		—
	Level 2
	Corporate notes		79,535		72		(54	)		—		79,553
	Total	$	171,881	$	72	$	(54	)	$	92,346	$	79,553
		June 30, 2013
									Estimated Market Value
		Amortized		Gross		Gross			Cash and Cash		Short-term
		Cost		Unrealized		Unrealized			Equivalents		Investments
				Gains		Losses
	Cash	$	60,082	$	—	$	—		$	60,082	$	—
	Level 1
	Certificates of deposit		15,365		—		—			12,758		2,607
	Money market funds		473		—		—			473		—
			15,838		—		—			13,231		2,607
	Level 2
	Commercial paper		3,993		—		(1	)		—		3,992
	Corporate notes		94,941		—		(456	)		—		94,485
			98,934		—		(457	)		—		98,477
	Total	$	174,854	$	—	$	(457	)	$	73,313	$	101,084
	The Company's Level 2 investments in the table above are classified as Level 2 items because quoted prices in an active market are not readily accessible for those specific financial assets, or the Company may have relied on alternative pricing methods that do not rely exclusively on quoted prices to determine the fair value of the investments.
	The Company reviews its investments to identify and evaluate investments that have an indication of possible impairment and has determined that no other-than-temporary impairments associated with credit losses were required to be recognized during the year ended June 30, 2014.
	Contractual maturities of available-for-sale securities at June 30, 2014 were as follows (in thousands):
		June 30, 2014
		Amortized		Fair Value
		Cost
	Due in 1 year or less	$	28,663	$	28,678
	Due in 1 - 2 years		25,049		25,050
	Due in 2 - 3 years		25,823		25,825
		$	79,535	$	79,553
	The following table summarizes the carrying values and estimated fair values of the Company's Convertible Notes (in thousands):
		June 30, 2014				June 30, 2013
		Carrying		Fair Value		Carrying			Fair Value
		Value				Value
	3.75% Convertible Notes	$	88,511	$	115,415	$	83,768		$	96,560
	3.50% Convertible Notes		44,654		79,388		115,000			144,302
	3.50% Series A Convertible Notes		62,447		125,065		—			—
	Total	$	195,612	$	319,868	$	198,768		$	240,862
	The long-term debt is measured on a non-recurring basis using Level 2 inputs based upon observable inputs of the Company's underlying stock price and the time value of the conversion option, since an observable quoted price of the Convertible Notes is not readily available.

Business_Combinations

Business Combinations	12 Months Ended
	Jun. 30, 2014
Business Combinations	'
Business Combinations	'
	5. Business Combinations
	Fiscal 2013 Acquisition
	On July 16, 2012, the Company acquired the remaining 90% of the outstanding shares of Morphormics, Inc., or Morphormics, a privately-held developer of medical imaging software based in North Carolina. This acquisition enables the Company to extend auto-contouring capabilities for both the CyberKnife and TomoTherapy systems to improve disease specific workflows. The Company previously held 10% of the outstanding shares of Morphormics, which had a carrying value of zero prior to the acquisition date and was valued at $0.7 million as of the acquisition date based on the fair value of the consideration paid. The acquisition was accounted for as a business combination, and accordingly, Morphormics' results of operations were included in the consolidated financial statements from July 16, 2012. This transaction was not considered a material business combination, and Company did not incur significant severance or acquisition-related costs in connection with the transaction.
	The fair value of total purchase consideration paid and payable for 100% of Morphormics' equity interest as of the acquisition date was as follows (in thousands):
	Cash paid and payable	$	5,385
	Fair value of pre-existing investment in Morphormics		662
	Total	$	6,047
	The total purchase price was allocated to the net tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date as follows (in thousands):
	Cash and cash equivalents	$	668
	Accounts receivable		283
	Other current assets		7
	Amortizable intangible assets—developed technology		5,100
	Goodwill		77
	Accrued compensation		(88	)
	Total purchase price	$	6,047
	Pro forma results of operations for the acquisition have not been presented because they are not material to the Company's consolidated statements of operations and comprehensive loss, balance sheets, or cash flows.

Goodwill_and_Purchased_Intangi

Goodwill and Purchased Intangible Assets	12 Months Ended
	Jun. 30, 2014
Goodwill and Purchased Intangible Assets	'
Goodwill and Purchased Intangible Assets	'
	6. Goodwill and Purchased Intangible Assets
	Goodwill
	Goodwill as of June 30, 2014 and 2013 and changes in the carrying amount of goodwill for the respective periods are as follows (in thousands):
		June 30,			June 30,
		2014			2013
	Balance at the beginning of the period	$	59,368		$	59,215
	Addition related to acquisition		—			77
	Currency translation and other adjustments		(1,277	)		76
	Balance at the end of the period	$	58,091		$	59,368
	In connection with the acquisition of TomoTherapy in fiscal year 2011, the Company recognized liabilities related to unrecognized tax benefits as part of purchase accounting. During its first quarter of fiscal year 2014, the Company determined that certain of these liabilities related to unrecognized tax benefits were recorded in error. The Company evaluated the effects of this error on the financial statements and concluded that the error was not material to any prior annual or interim periods or the current period. In September of 2013, the Company reduced goodwill and accrued liabilities by $1.3 million to remove the liability recorded in error.
	In fiscal 2014 the Company performed its annual goodwill impairment test. Based on this analysis, the Company determined that there was no impairment to goodwill. The Company will continue to monitor its recorded goodwill for indicators of impairment.
	Purchased Intangible Assets
	The Company's intangible assets associated with completed acquisitions are as follows (in thousands):
				June 30, 2014								June 30, 2013
		Useful		Gross			Accumulated			Net		Gross		Accumulated			Net
		Lives		Carrying			Amortization			Amount		Carrying		Amortization			Amount
				Amount								Amount
		(in years)
	Developed technology	5 - 6		$	46,747		$	(23,230	)	$	23,517	$	46,747	$	(15,276	)	$	31,471
	Distributor license	1.5 - 2.5			2,037			(2,037	)		—		2,043		(1,618	)		425
				$	48,784		$	(25,267	)	$	23,517	$	48,790	$	(16,894	)	$	31,896
	During the year ended June 30, 2013, the Company recorded an impairment charge of approximately $12.2 million related to IPR&D technology due to a decrease in projected future usage of the technology.
	The Company did not identify any triggering events that would indicate potential impairment of its definite-lived intangible and long-lived assets as of June 30, 2014 and 2013.
	Amortization expense, excluding impairment charges related to purchased intangible assets was $8.4 million, $10.4 million and $16.2 million for the years ended June 30, 2014, 2013 and 2012, respectively.
	The estimated future amortization expense of purchased intangible assets as of June 30, 2014 is as follows (in thousands):
	Year Ending June 30,	Amount
	2015	$	7,953
	2016		7,953
	2017		7,568
	2018		43
	Thereafter		—
		$	23,517

Investment_in_CPAC

Investment in CPAC	12 Months Ended
	Jun. 30, 2014
Investment in CPAC	'
Investment in CPAC	'
	7. Investment in CPAC
	In April 2008, TomoTherapy established an affiliate, CPAC, to develop a compact proton therapy system for the treatment of cancer. Between the date of formation of CPAC through December 2012, the Company and TomoTherapy contributed both cash and intellectual property to CPAC, resulting in a combined equity interest of approximately 15.4% of the outstanding stock of CPAC and approximately 16.3% on a fully diluted basis. As of the Company's acquisition of TomoTherapy on June 10, 2011, the Company determined that CPAC was a variable interest entity, as CPAC depended on the Company, TomoTherapy and other investors to fund its operations. Under the accounting standards for consolidating variable interest entities, the consolidating investor is the entity with the power to direct the activities of the venture that most significantly impact the venture's economic performance and with the obligation to absorb losses or the right to receive benefits from the venture that could potentially be significant to the venture. Although the Company and its subsidiary held less than a 50% ownership interest in CPAC, it was determined that the Company met these two characteristics, and therefore, was the primary beneficiary of CPAC. The Company consolidated the results of operations of CPAC from June 10, 2011 to December 21, 2012.
	On December 21, 2012, the Company and CPAC entered into a Purchase Agreement and Release, or Purchase Agreement, which provided for all the equity and debt investments held by the Company in CPAC to be purchased by CPAC for a nominal consideration. In addition, the Company assigned all its rights to the Dielectric Wall Accelerator, or DWA technology licensed from Lawrence Livermore National Security, LLC to CPAC. As a result of the Purchase Agreement, the Company concluded that it was no longer the primary beneficiary of CPAC since it did not have any variable interest in CPAC. In the second quarter of fiscal 2013, the Company deconsolidated CPAC and recorded a loss of $3.4 million, resulting from the write-down of the carrying value of CPAC's net liabilities, the write-off of receivables from CPAC and the non-controlling interest in CPAC, net of cash consideration received. The results of operations of CPAC, including the loss on deconsolidation of CPAC and the losses attributable to the non-controlling interest recorded for the years ended June 30, 2013 and 2012 have been presented as discontinued operations in the consolidated statements of operations and comprehensive loss.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2014
Commitments and Contingencies	'
Commitments and Contingencies	'
	8. Commitments and Contingencies
	Operating Lease Agreements and Long-term Debt
	The Company leases office and manufacturing space under non-cancelable operating leases with various expiration dates through December 2023. Rent expense was $6.5 million, $8.7 million and $7.1 million for the years ended June 30, 2014, 2013 and 2012, respectively. The terms of the facility leases provide for rental payments on a graduated scale. The Company recognizes rent expense on a straight-line basis over the lease period, and has accrued for rent expense incurred but not paid.
	The Company is required to make semi-annual interest payments on the Convertible Notes. See Note 13, Debt, for details.
	Future minimum lease payments under non-cancelable operating lease agreements and long-term principal and interest on the Convertible Notes as of June 30, 2014 are as follows (in thousands):
	Year Ending June 30,	Operating		Long-term
		Leases		Debt(1)
	2015	$	6,427	$	7,775
	2016		8,205		7,775
	2017		8,295		104,338
	2018		7,931		117,348
	2019		4,818		—
	Thereafter		17,969		—
	Total	$	53,645	$	237,236
	-1
	These amounts represent principal and interest cash payments over the contractual life of the debt obligations, including anticipated interest payments that are not recorded on the Company's consolidated balance sheet. Any conversion, redemption or purchase of Convertible Notes would impact cash payments noted in the preceding table.
	The Company enters into standard indemnification agreements with its landlords and all superior mortgagees and their respective directors, officers' agents, and employees in the ordinary course of business. Pursuant to these agreements, the Company will indemnify, hold harmless, and agree to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the landlords, in connection with any loss, accident, injury, or damage by any third party with respect to the leased facilities. The term of these indemnification agreements is from the commencement of the lease agreements until termination of the lease agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, historically the Company has not incurred claims or costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has recorded no liability associated with its indemnification agreements as it is not aware of any pending or threatened actions that represent probable losses as of June 30, 2014.
	Royalty Agreement
	The Company has an exclusive license agreement with the Wisconsin Alumni Research Foundation, or WARF, to make, use, sell and otherwise distribute products under certain of WARF's patents anywhere in the world. The Company is required to pay WARF a royalty for each TomoTherapy System sold that includes the licensed technology. The license agreement expires upon expiration of the patents and may be terminated earlier if the Company so elects. WARF has the right to terminate the license agreement if the Company does not meet the minimum royalty obligation of $0.3 million per year, or if the Company commits any breach of the license agreement's covenants. The Company recorded royalty costs of $0.7 million, $0.6 million and $1.0 million for the years ended June 30, 2014, 2013 and 2012, respectively, which were recorded in cost of revenue or deferred cost of revenue. The Company had accrued liabilities of approximately $0.1 million at June 30, 2014 and 2013 related to this agreement.
	Software License Indemnity
	Under the terms of the Company's software license agreements with its customers, the Company agrees that in the event the software sold infringes upon any patent, copyright, trademark, or any other proprietary right of a third party, it will indemnify its customer licensees against any loss, expense, or liability from any damages that may be awarded against its customer. The Company includes this infringement indemnification in all of its software license agreements and selected managed services arrangements. In the event the customer cannot use the software or service due to infringement and the Company cannot obtain the right to use, replace or modify the license or service in a commercially feasible manner so that it no longer infringes, then the Company may terminate the license and provide the customer a refund of the fees paid by the customer for the infringing license or service. The Company has not recorded any liability associated with this indemnification, as it is not aware of any pending or threatened actions that represent probable losses as of June 30, 2014.
	Litigation
	From time to time, the Company is involved in legal proceedings arising in the ordinary course of its business. Currently, management believes the Company does not have any probable and estimable losses related to any current legal proceedings and claims that would individually or in the aggregate materially adversely affect its financial condition or operating results. For certain legal proceedings, management believes that there is a reasonable possibility that losses may be incurred. Management currently estimates a range of loss (in excess of amounts accrued) between zero and $0.5 million in the aggregate for such legal proceedings, where it is possible to make such estimates. Litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company's control. Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related to legal matters that could have a material impact on its results of operations, financial position and cash flows.
	Best Medical Trade Secret Litigation
	On September 3, 2009, Best Medical International, Inc., or Best Medical, filed a lawsuit against the Company in the U.S. District Court for the Western District of Pennsylvania, claiming that the Company induced certain individuals to leave the employment of Best Medical and join the Company in order to gain access to Best Medical's confidential information and trade secrets. Best Medical is seeking monetary damages and other relief. On October 25, 2011, the court presiding over the case granted summary judgment in favor of the Company on all counts. On November 21, 2011, Best Medical filed a notice of appeal. On December 22, 2011, the court awarded attorney fees and costs to the Company and ordered the Company to file an accounting of its fees and costs. Following the filing of the accounting of the Company's fees and costs, the magistrate judge presiding over the case issued a report on the Company's accounting and recommended an award to the Company in the amount of $0.5 million in attorney fees and costs, which was adopted in its entirety by the District Court on September 27, 2013. On July 3, 2013, the Court of Appeals for the Third Circuit issued a briefing schedule for the appeal of this case. Best Medical's brief was filed on September 16, 2013 and the Company's brief was filed on December 30, 2013. Best Medical filed its reply brief on January 10, 2014. The parties reached a settlement effective June 9, 2014. The case, including the related appeals, was dismissed with prejudice on June 26, 2014.
	Best Medical Patent Litigation
	On August 6, 2010, Best Medical filed an additional lawsuit against the Company in the U.S. District Court for the Western District of Pennsylvania, claiming that the Company has infringed U.S. Patent No. 5,596,619, a patent that Best Medical alleges protects a method and apparatus for conformal radiation therapy. In December 2010, Best Medical amended its complaint by claiming that the Company also infringed U.S. Patent Nos. 6,038,283 and 7,266,175, both of which Best Medical alleges cover methods and apparatus for conformal radiation therapy. In March 2011, the court dismissed with prejudice all counts against the Company, except for two counts of alleged willful infringement of two of the patents. Following several procedural rulings by the court, Best Medical moved to voluntarily dismiss one of the two remaining patent claims on June 28, 2011, which the court granted on June 30, 2011, leaving only one patent (U.S. Patent No. 6,038,283) at issue in the case. The parties failed to a reach settlement during mandatory settlement conferences held in March 2013, May 2013 and April 2014. Best Medical was seeking declaratory and injunctive relief, as well as unspecified compensatory and treble damages and other relief. The parties reached a settlement effective June 9, 2014. The case was dismissed with prejudice on June 26, 2014.
	Rotary Systems
	On April 28, 2011, a former supplier to TomoTherapy, Rotary Systems Incorporated, filed suit in Minnesota state court, Tenth Judicial District, Anoka County, against TomoTherapy alleging misappropriation of trade secrets, as well as several other counts alleging various theories of injury. Rotary Systems alleges TomoTherapy misappropriated Rotary Systems' trade secrets pertaining to a component previously purchased from Rotary Systems, which component TomoTherapy now purchases from a different supplier. The suit alleges TomoTherapy improperly supplied the alleged trade secrets to its present supplier, Dynamic Sealing Technologies Inc. (also a named defendant in the suit). Rotary Systems has made an unspecified claim for damages of greater than $50,000. TomoTherapy moved to dismiss the case on May 19, 2011, and on August 29, 2011, the court granted the motion to dismiss with respect to all counts other than the count alleging misappropriation of trade secrets. On May 21, 2012, the court granted the Company's motion for sanctions, in part, and gave Rotary Systems sixty days to identify the alleged trade secrets with specificity or face dismissal of its claim with prejudice. The court held a hearing on September 20, 2012 to review Rotary Systems' amended complaint and set a calendar for discovery. The court ruled on the amended complaint, and the parties have started discovery, which was originally expected to be completed by October 2013. The parties jointly asked the court to extend discovery until February 2014. The Company filed a motion for summary judgment and, on September 11, 2013, the court held a hearing on the Company's motion for summary judgment and to stay discovery pending the ruling on the summary judgment motion. On December 5, 2013, the court ruled in favor of the Company. Rotary Systems filed its notice of appeal on January 29, 2014. On April 14, 2014, Rotary Systems filed its appellant brief with the court. On June 2, 2014, the Company filed its response brief, and on June 27, 2014, Rotary Systems filed its reply brief with the court. The parties are awaiting a hearing date from the court for oral arguments. The Company anticipates that the argument will be heard in the fall of 2014.
	Sarif Biomedical Patent Litigation
	On January 28, 2013, Sarif Biomedical filed a patent infringement complaint against the Company in the U.S. District Court for the District of Delaware. The complaint alleges the Company's CyberKnife System directly infringes U.S. Patent No. 5,755,725 and seeks unspecified monetary damages for the alleged infringement. Accuray filed an answer to the complaint in March 2013. The parties have exchanged initial discovery requests and responses. The court issued a scheduling order on April 29, 2014. Accuray made its first document production on May 30, 2014. Discovery closes on May 5, 2015, and trial is set for April 11, 2016.
	Cowealth Medical
	On February 27, 2014, Cowealth Medical Holding Co., Ltd. ("Cowealth"), Accuray's former distributor in China, submitted a request for arbitration with the International Chamber of Commerce International Court of Arbitration ("ICC") alleging, among other matters, that Accuray breached its distributor agreement with Cowealth by wrongfully terminating Cowealth as its distributor and misappropriated certain of Cowealth's confidential information. Cowealth is seeking damages and injunctive relief. Accuray's answer and counterclaim were submitted to the ICC on May 12, 2014, and Cowealth served its reply on June 27, 2014. A hearing has been set for January 27, 2015.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2014
Stockholders' Equity	'
Stockholders' Equity	'
	9. Stockholders' Equity
	In fiscal 2012, the Company retired 2,140,018 shares of its common stock that were repurchased in prior years and accounted for as treasury stock. The Company did not have an active stock repurchase program at June 30, 2014.
	At June 30, 2014, the Company had 13.2 million and 21.6 million shares of common stock reserved for future issuance to the holders of the 3.75% Convertible Senior Notes and 3.50% Convertible Senior Notes (including Series A Convertible Senior Notes), respectively, and had 13.8 million shares of common stock reserved for issuance under the stock incentive plans and the employee stock purchase plan.

Stock_Incentive_Plan_and_Emplo

Stock Incentive Plan and Employee Stock Purchase Plan	12 Months Ended
	Jun. 30, 2014
Stock Incentive Plan and Employee Stock Purchase Plan	'
Stock Incentive Plan and Employee Stock Purchase Plan	'
	10. Stock Incentive Plan and Employee Stock Purchase Plan
	As of June 30, 2014, the Company had two outstanding stock incentive plans: the 2007 Stock Incentive Plan, or the 2007 Plan; and the 1998 Stock Incentive Plan, or the1998 Plan. The 2007 Plan permits the granting of stock options, restricted stock awards, or RSAs and restricted stock units, or RSUs. The vesting of RSUs under the 2007 Plan may be time-based (over the requisite service period), performance-based, or PSUs or market-based, or MSUs. Only employees of the Company are eligible to receive incentive stock options. Non-employees may be granted non-qualified options.
	Stock options granted under the 2007 Plan have an exercise price of at least 100% of the fair market value of the underlying stock on the grant date and no less than 85% of the fair value for non-qualified stock options. The stock options have 10 year contractual terms and generally become exercisable for 25% of the option shares one year from the date of grant and then ratably over the following 36 months. Time-based RSUs generally vest 25% of the share units covered by the grant on each of the first through fourth anniversaries of the date of the grant. However, certain of the outstanding RSUs vest 50% upon the first anniversary year of the grant date, and 50% upon the second anniversary year of the grant date. The Board of Directors has the discretion to use different vesting schedules.
	As of June 30, 2014, the 1998 Plan continued to remain in effect; however, the Company can no longer make equity awards under the plan.
	The following table summarizes the share-based compensation charges included in the Company's consolidated statements of operations and comprehensive loss (in thousands):
		Years ended June 30,
		2014			2013			2012
	Cost of revenue	$	1,912		$	1,498		$	1,672
	Research and development		2,585			1,949			2,340
	Selling and marketing		2,059			1,121			729
	General and administrative		4,757			3,648			3,717
		$	11,313		$	8,216		$	8,458
	For the years ended June 30, 2014, 2013 and 2012, the Company capitalized share-based compensation costs of $0.5 million, $0.6 million and $0.4 million, respectively, as components of inventory.
	Stock Options
	The Company did not grant any stock options in the year ended June 30, 2014. The Company used the Black-Scholes option pricing model to measure the fair value of stock options grants. During the years ended June 30, 2013 and 2012, the following weighted average assumptions were used:
		Years Ended June 30,
		2013		2012
	Risk-free interest rate	0.87% - 1.15%		0.85% - 1.72%
	Dividend yield	—		—
	Expected life	6.25		6.25
	Expected volatility	52.7% - 63.2%		52.0% - 52.9%
	A summary of option activity under the Company's Incentive Plan during the fiscal years is presented below (in thousands, except per share and term amounts):
		Options			Weighted			Weighted			Aggregate
		Outstanding			Average			Average			Intrinsic
					Exercise Price			Remaining			Value
								Contractual			(in thousands)
								Life (In Years)
	Balance at June 30, 2011		8,336		$	7.39			5.13		$	19,131
	Options granted		1,399		$	4.53
	Options exercised		(746	)	$	2.5
	Options forfeited/expired		(1,116	)	$	9.79
	Balance at June 30, 2012		7,873		$	7			5.57		$	12,359
	Options granted		1,250		$	6.54
	Options exercised		(1,515	)	$	2.77
	Options forfeited/expired		(2,764	)	$	8.86
	Balance at June 30, 2013		4,844		$	7.15			6.17		$	2,771
	Options granted		—		$	—
	Options exercised		(1,062	)	$	5.01
	Options forfeited/expired		(573	)	$	9.49
	Balance at June 30, 2014		3,209		$	7.44			5.38		$	8,251
	Vested or Expected to vest at June 30, 2014		3,209		$	7.44			5.38		$	8,251
	Exercisable at June 30, 2014		2,470		$	7.87			4.58		$	6,191
	The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the fair value of the Company's common stock on June 30, 2014 of $8.80 and the exercise price of the options) that would have been received by option holders if all options exercisable had been exercised on June 30, 2014. The total intrinsic value of options exercised in the years ended June 30, 2014, 2013, and 2012 was approximately $3.8 million, $4.5 million and $2.9 million, respectively.
	During the years ended June 30, 2014, 2013 and 2012, the Company recognized $1.7 million, $2.9 million and $3.5 million, respectively, of share-based compensation expense for stock options granted to employees. The weighted average fair value of options granted was $3.48 and $2.30 per share for the years ended June 30, 2013 and 2012.
	Tax benefits from tax deductions for exercised options and disqualifying dispositions in excess of the deferred tax asset attributable to stock compensation costs for such options are credited to additional paid-in capital. Realized excess tax benefits related to stock options exercises was zero for each of the years ended June 30, 2014, 2013 and 2012.
	As of June 30, 2014, there was approximately $2.2 million of unrecognized compensation cost, net of estimated forfeitures, related to unvested stock options, which is expected to be recognized over a weighted average period of 2.08 years.
	The following table summarizes information about outstanding and exercisable options at June 30, 2014 (in thousands, except years and exercise prices):
		Options Outstanding									Options Exercisable
	Exercice Prices	Number			Weighted Average			Weighted			Number			Weighted
		Outstanding			Remaining Contractual			Average			Outstanding			Average
					Life (Years)			Exercise Price						Exercise Price
	$3.50 - 4.01		611			4.73		$	3.81			474		$	3.75
	$4.23 - 5.68		477			4.96			5.2			402			5.28
	$5.74 - 6.28		518			6.97			6.14			326			6.07
	$6.31 - 6.58		397			4.66			6.47			359			6.47
	$6.63 - 6.90		111			5.59			6.67			105			6.67
	$6.96		422			8.15			6.96			174			6.96
	$7.06 - 10.36		359			4.42			8.82			316			9
	$13.05 - 18.40		196			3.14			16			196			16
	$22.70		3			1.86			22.7			3			22.7
	$28.47		115			2.61			28.47			115			28.47
	Total Outstanding		3,209			5.38		$	7.44			2,470		$	7.87
	Restricted Stock
The following table summarizes the activity of RSUs, PSUs and MSUs:
Unvested Restricted Stock	Restricted			Performance			Market			Total Number of			Weighted Average
	Stock Units			Stock Units			Stock Units			Shares Underlying			Grant Date Fair
	(000's)			(000's)			(000's)			Stock Awards (000's)			Value Per Share
Unvested at June 30, 2011		658			—			—			658		$	6.97
Granted		1,047			954			—			2,001			4.53
Vested		(302	)		—			—			(302	)		4.47
Cancelled/Forfeited		(193	)		(66	)		—			(259	)		5.67
Unvested at June 30, 2012		1,210			888			—			2,098			5.16
Granted		2,200			36			426			2,662			5.52
Vested		(526	)		(18	)		—			(544	)		5.18
Cancelled/Forfeited		(460	)		(350	)		(19	)		(829	)		5.18
Unvested at June 30, 2013		2,424			556			407			3,387			5.66
Granted		2,125			70			735			2,930			7.28
Vested		(888	)		(25	)		—			(913	)		8.7
Cancelled/Forfeited		(545	)		(576	)		(336	)		(1,457	)		5.44
Unvested at June 30, 2014		3,116			25			806			3,947		$	6.24
As of June 30, 2014, there was approximately $17.2 million of unrecognized compensation cost, net of estimated forfeitures, related to restricted stock, which is expected to be recognized over a weighted average period of 2.44 years.
Restricted Stock Units
The Company recognized $6.4 million, $3.6 million and $2.5 million of share-based compensation expense, net of estimated forfeitures, related to RSUs during the years ended June 30, 2014, 2013 and 2012. The weighted average grant date fair value per share of RSUs was $7.32, $5.89 and $4.80 for the years ended June 30, 2014, 2013 and 2012, respectively. As of June 30, 2014, there was approximately $14.1 million of unrecognized compensation cost, net of estimated forfeitures, related to RSUs. The aggregate fair market value of RSUs that vested during the year ended June 30, 2014 was $7.7 million.
The Company recognized $0.3 million and $1.4 million of share-based compensation expense during the years ended June 30, 2013 and 2012, respectively, related to RSAs assumed in connection with the acquisition of TomoTherapy. The expense recognized in fiscal 2014 was immaterial.
Performance Stock Units
During fiscal 2012, the Compensation Committee approved the grant of 1.0 million PSUs to certain employees of the Company. The PSUs were cancelled in fiscal 2014 as it was determined that the Company did not achieve the requisite performance targets.
The Company recognized $0.1 million of share-based compensation expense, net of estimated forfeitures, related to PSUs during the year ended June 30, 2014. The expense recognized during the year ended June 30, 2013 was immaterial.
Market Stock Units
The Compensation committee approved the performance equity program, referred to as the market stock unit program, or MSU program, in October 2012. The Company's MSU Program uses the Russell 2000 index as a performance benchmark and requires that the Company's total stockholder return match or exceed that of the Russell 2000. Based on a sliding scale of how much the Company's total stockholder return outperforms the Russell 2000 benchmark, the participating executives can earn up to a maximum of 150% of the target number of shares over two measurement periods. The Company uses a Monte-Carlo simulation to calculate the fair value of the award on the grant date. The Company recognized $1.8 million and $0.3 million of share-based compensation expense, net of estimated forfeitures, related to MSUs during the years ended June 30, 2014 and 2013. The weighted average grant date fair value per share of MSUs was $7.18 and $5.39 for the years ended June 30, 2014 and 2013, respectively. As of June 30, 2014, there was approximately $3.1 million of unrecognized compensation cost, net of estimated forfeitures, related to MSUs. There were no vested MSUs and 0.2 million of MSUs were cancelled in fiscal 2014 as the performance targets were not achieved for the first measurement period. Assuming 100% performance target will be achieved, 0.5 million and 0.3 million of MSUs will vest by the end of fiscal 2015 and 2016, respectively.
Employee Stock Purchase Plan
Under the Company's 2007 Employee Stock Purchase Plan, or ESPP, qualified employees are permitted to purchase the Company's common stock at 85% of the lower of the fair market value of the common stock on the commencement date of each offering period or the fair market value on the specified purchase date. The ESPP is deemed compensatory and compensation costs are accounted for under ASC 718, Stock Compensation. Employees' payroll deductions may not exceed 10% of their salaries. Employees may purchase up to 2,500 shares per period provided that the value of the shares purchased in any calendar year may not exceed $25,000, as calculated pursuant to the purchase plan.
The Company estimates the fair value of ESPP shares at the date of grant using the Black-Scholes option pricing model. The weighted average assumptions were as follows:
	Years Ended June 30,
	2014		2013		2012
Risk-free interest rate	0.06% - 0.13%		0.07% - 0.14%		0.05% - 0.12%
Dividend yield	—		—		—
Expected life	0.5 - 1.0		0.5		0.5
Expected volatility	27.5% - 46.5%		40.3% - 53.7%		33.6% - 50.6%
The risk-free rate for the expected term of the ESPP option was based on the U.S. Treasury Constant Maturity rate for each offering period; expected volatility was based on the historical volatility of the Company's common stock; and the expected term was based upon the offering period of the ESPP. For the years ended June 30, 2014, 2013 and 2012, the Company recognized $1.3 million, $1.3 million and $1.1 million, respectively, of compensation expense related to its ESPP.
The Company issued 0.7 million shares under the ESPP in fiscal 2014 and 2013, respectively, at a weighted average price per share of $5.44 and $4.89, respectively. As of June 30, 2014, total unrecognized compensation cost related to the ESPP plan was $0.7 million, which the Company expects to recognize over a weighted average period of 0.6 years.

Income_Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2014
Income Taxes	'
Income Taxes	'
	11. Income Taxes
	Loss before provision for income taxes on the accompanying statements of operations and comprehensive loss included the following components (in thousands):
		Years Ended June 30,
		2014			2013			2012
	Domestic	$	(42,485	)	$	(103,964	)	$	(75,391	)
	Foreign		10,125			10,176			6,636
	Total worldwide	$	(32,360	)	$	(93,788	)	$	(68,755	)
	The provision for income taxes consisted of the following (in thousands):
		Years Ended June 30,
		2014			2013			2012
	Current:
	Federal	$	—		$	—		$	—
	State		78			(21	)		(7	)
	Foreign		2,918			2,647			2,107
	Total current		2,996			2,626			2,100
	Deferred:
	Federal		—			—			—
	State		—			—			—
	Foreign		92			947			495
	Total deferred		92			947			495
	Total provision for income taxes	$	3,088		$	3,573		$	2,595
	Income tax payable was $2.0 million and $1.2 million at June 30, 2014 and 2013, respectively. A reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of operations and comprehensive loss is as follows (in thousands):
		Years Ended June 30,
		2014			2013			2012
	U.S. federal taxes (benefit):
	At federal statutory rate	$	(11,326	)	$	(32,826	)	$	(24,064	)
	State tax, net of federal benefit		78			(21	)		(7	)
	Stock-based compensation expense		332			4,061			3,645
	Change in valuation allowance		13,997			33,454			24,796
	Credits		(114	)		(1,272	)		(846	)
	Other		640			69			(1,245	)
	Foreign taxes		(519	)		108			316
	Total	$	3,088		$	3,573		$	2,595
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's net deferred tax assets were as follows (in thousands):
		June 30,
		2014			2013
	Deferred tax assets:
	Federal and state net operating losses	$	116,734		$	105,110
	Accrued expenses and reserves		6,410			7,021
	Deferred revenue		1,217			1,913
	Credits		16,686			16,636
	Share-based compensation expense		5,391			10,691
	Unicap		1,710			1,540
	Other		904			623
	Total deferred tax assets		149,052			143,534
	Deferred tax liabilities:
	Debt discount		(7,087	)		(4,884	)
	Fixed assets/intangibles		(8,268	)		(11,740	)
	Foreign currency differences		(7	)		(1,697	)
	Total deferred tax liabilities		(15,362	)		(18,321	)
	Valuation allowance		(133,039	)		(124,781	)
	Net deferred tax assets	$	651		$	432
	The Company has not provided for U.S. income taxes on undistributed earnings of its foreign subsidiaries because it intends to permanently re-invest these earnings outside the U.S. The cumulative amount of such undistributed earnings upon which no U.S. income taxes have been provided as of June 30, 2014 was $14.7 million. It is not practicable to determine the income tax liability that might be incurred if these earnings were to be repatriated to the U.S.
	As of June 30, 2014 the Company had approximately $320.5 million and $166.8 million in federal and state net operating loss carryforwards, respectively. The federal and state carryforwards expire in varying amounts beginning in 2019 for federal and 2015 for state purposes. Such net operating loss carryforwards include excess tax benefits from employee stock option exercises which, in accordance with guidance for income tax accounting, have not been recorded within the Company's deferred tax asset balances. The Company will record approximately $3.9 million as a credit to additional paid-in capital as and when such excess benefits are ultimately realized.
	In addition, as of June 30, 2014, the Company had federal and state research and development tax credits of approximately $16.1 million and $15.7 million, respectively. The federal research credits will begin to expire in 2019, the California research credits have no expiration date, and the other state research credits began to expire in 2015.
	Utilization of the Company's net operating loss and credit carryforwards is subject to annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code and similar state provisions. The acquisition of TomoTherapy and the resulting Section 382 limitation should not result in the expiration of net operating losses or credits due to the Section 382 limitation.
	Based on the available objective evidence and history of losses, the Company has established a 100% valuation allowance against the combined domestic net deferred tax assets of Accuray and TomoTherapy due to uncertainty surrounding the realization of such deferred tax assets.
	The aggregate changes in the balance of gross unrecognized tax benefits were as follows (in thousands):
		Years Ended June 30,
		2014			2013			2012
	Balance at beginning of year	$	16,749		$	15,147		$	14,158
	Tax positions related to current year:
	Additions		1,489			1,781			1,129
Tax positions related to prior years:
Additions		—			564			40
Reductions		(1,069	)		(743	)		(180	)
Balance at end of year	$	17,169		$	16,749		$	15,147
The calculation of unrecognized tax benefits involves dealing with uncertainties in the application of complex global tax regulations. Management regularly assesses the Company's tax positions in respect to legislative, bilateral tax treaty, regulatory and judicial developments in the countries in which the Company does business. The reduction in prior years tax positions primarily relates to lapses of applicable statutes of limitations. The Company anticipates that except for $0.3 million in uncertain tax positions that may be reduced related to the lapse of various statutes of limitation, there will be no material changes in uncertain tax positions in the next 12 months. As of June 30, 2014, the amount of gross unrecognized tax benefits was $17.2 million of which $10.2 million would affect the Company's effective tax rate if realized.
The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of June 30, 2014 and 2013, the Company had approximately $0.7 million of accrued interest and penalties related to uncertain tax positions.
The Company files income tax returns in the United States federal, various states and foreign jurisdictions. Due to attributes being carried forward and utilized during open years, the statute of limitations remains open for the U.S. federal jurisdiction and domestic states for tax years from 1999 and forward. The material foreign jurisdictions are France, Switzerland, and Japan, whose tax years remain open from 2011, 2006, and 2006, respectively.
The Company is also subject to periodic examination of its income tax returns by the Internal Revenue Service (IRS) and other tax authorities, and in some cases the Company has received additional tax assessments which have not been significant. Currently, the Company is under audit by the German tax authorities which is in the early stages of the audit.

Other_Income_Expense_Net

Other Income (Expense), Net	12 Months Ended
	Jun. 30, 2014
Other Income (Expense), Net	'
Other Income (Expense), Net	'
	12. Other Income (Expense), Net
	Other income (expense), net consisted of the following (in thousands):
		Years Ended June 30,
		2014			2013			2012
	Interest expense on convertible notes	$	(14,287	)	$	(10,378	)	$	(7,397	)
	Foreign currrency transaction loss		(91	)		(2,503	)		(4,386	)
	Other		162			(252	)		(738	)
	Total other expense, net	$	(14,216	)	$	(13,133	)	$	(12,521	)

Debt

Debt	12 Months Ended
	Jun. 30, 2014
Debt	'
Debt	'
	13. Debt
	3.75% Convertible Senior Notes due August 2016
	On August 1, 2011, the Company issued the 3.75% Convertible Notes to certain qualified institutional buyers or QIBs. The Securities were offered and sold to the QIBs pursuant to Rule 144A under the Securities Act of 1933, as amended or Rule 144A. The net proceeds from the $100 million offering, after deducting the initial purchaser's discount and commission and the related offering costs, were approximately $96.1 million. The offering costs and the initial purchaser's discount and commission (which are recorded in Other Assets) are both being amortized to interest expense using the effective interest method over five years. The 3.75% Convertible Notes bear interest at a rate of 3.75% per year, payable semi-annually in arrears in cash on February 1 and August 1 of each year, beginning on February 1, 2012. The 3.75% Convertible Notes will mature on August 1, 2016, unless earlier repurchased, redeemed or converted.
	The 3.75% Convertible Notes were issued under an Indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Holders of the Securities may convert their 3.75% Convertible Notes at any time on or after May 1, 2016 until the close of business on the business day immediately preceding the maturity date. Prior to May 1, 2016, holders of the Securities may convert their 3.75% Convertible Notes only under the following circumstances: (1) during any calendar quarter after the calendar quarter ending September 30, 2011, and only during such calendar quarter, if the closing sale price of the Company's common stock for each of 20 or more trading days in the 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter exceeds 130% of the conversion price in effect on the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading-day period (such five consecutive trading-day period, the "Note Measurement Period") in which the trading price per $1,000 principal amount of 3.75% Convertible Notes for each trading day of that Note Measurement Period was equal to or less than 98% of the product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day; (3) if the Company calls any or all of the 3.75% Convertible Notes for redemption, at any time prior to the close of business on the business day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate transactions as described in the Indenture. Upon conversion by holders of the 3.75% Convertible Notes, the Company will have the right to pay or deliver, as the case may be, cash, shares of common stock of the Company or a combination thereof, at the Company's election. At any time on or prior to the 33rd business day immediately preceding the maturity date, the Company may irrevocably elect to (a) deliver solely shares of common stock of the Company in respect of the Company's conversion obligation or (b) pay cash up to the aggregate principal amount of the 3.75% Convertible Notes to be converted and pay or deliver, as the case may be, cash, shares of common stock of the Company or a combination thereof in respect of the remainder, if any, of the Company's conversion obligation in excess of the aggregate principal amount of the 3.75% Convertible Notes being converted. The initial conversion rate is 105.5548 shares of the Company's common stock per $1,000 principal amount of 3.75% Convertible Notes (which represents an initial conversion price of approximately $9.47 per share of the Company's common stock). The conversion rate, and thus the conversion price, are subject to adjustment as further described below.
	Holders of the 3.75% Convertible Notes who convert their Securities in connection with a "make-whole fundamental change," as defined in the Indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a "fundamental change," as defined in the Indenture, holders of the 3.75% Convertible Notes may require the Company to purchase all or a portion of their 3.75% Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of 3.75% Convertible Notes, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date.
	On or after August 1, 2014 and prior to the maturity date, the Company may redeem for cash all or a portion of the 3.75% Convertible Notes if the closing sale price of its common stock exceeds 130% of the applicable conversion price (the initial conversion price is approximately $9.47 per share of common stock) of such 3.75% Convertible Notes for at least 20 trading days during any consecutive 30 trading-day period (including the last trading day of such period).
	In accordance with Accounting Standards Codification, or ASC 470-20, Debt with Conversion and Other Options, the Company separately accounts for the liability and equity conversion components of the 3.75% Convertible Notes. The principal amount of the liability component of the 3.75% Convertible Notes was $75.9 million as of the date of issuance based on the present value of its cash flows using a discount rate of 10%, our approximate borrowing rate at the date of the issuance for a similar debt instrument without the conversion feature. The carrying value of the equity conversion component was $24.1 million. A portion of the initial purchaser's discount and commission and the offering costs totaling $0.9 million was allocated to the equity conversion component. The liability component is being accreted to the principal amount of the 3.75% Convertible Notes using the effective interest method over five years.
	3.50% Convertible Senior Notes due February 2018
	In February 2013, the Company issued $115.0 million aggregate principal amount of its 3.50% Convertible Notes to certain QIBs. The 3.50% Convertible Notes were offered and sold to the QIBs pursuant to Rule 144A. The net proceeds from the offering, after deducting the initial purchaser's discount and commission and the related offering costs, were approximately $110.5 million. The offering costs and the initial purchaser's discount and commission (which are recorded in Other Assets) are both being amortized to interest expense using the effective interest method over five years. The 3.50% Convertible Notes bear interest at a rate of 3.50% per year, payable semi-annually in arrears in cash on February 1 and August 1 of each year, beginning on August 1, 2013. The 3.50% Convertible Notes will mature on February 1, 2018, unless earlier repurchased, redeemed or converted.
	In April 2014, through a series of transactions, the Company refinanced approximately $70.3 million aggregate principal amount of the 3.50% Convertible Notes with approximately $70.3 million aggregate principal amount of the Company's new 3.50% Series A Convertible Senior Notes due 2018 (the "3.50% Series A Convertible Notes"). The remaining balance of the 3.50% Convertible Notes was $44.7 million as of June 30, 2014.
	The 3.50% Convertible Notes were issued under an Indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Holders of the 3.50% Convertible Notes may convert their 3.50% Convertible Notes at any time until the close of business on the business day immediately preceding the maturity date. The 3.50% Convertible Notes are convertible, as described below into common stock of the Company at an initial conversion rate equal to 187.6877 shares of common stock per $1,000 principal amount of the 3.50% Convertible Notes, which is equivalent to a conversion price of approximately $5.33 per share of common stock, subject to adjustment.
	Holders of the 3.50% Convertible Notes who convert their 3.50% Convertible Notes in connection with a "make-whole fundamental change", as defined in the Indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a "fundamental change," as defined in the Indenture, holders of the 3.50% Convertible Notes may require the Company to purchase all or a portion of their 3.50% Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of 3.50% Convertible Notes, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date.
	In accordance with guidance in ASC 470-20, Debt with Conversion and Other Options and ASC 815-15, Embedded Derivatives, the Company determined that the embedded conversion components of the 3.50% Convertible Note do not require bifurcation and separate accounting. The remaining $44.7 million principal amount of the 3.50% Convertible Note has been recorded in Long-term Debt on the consolidated balance sheet as of June 30, 2014.
	3.50% Series A Convertible Senior Notes due February 2018
	On April 17, 2014, the Company entered into note exchange agreements with certain holders (the "Participating Holders") of the 3.50% Convertible Notes to refinance approximately $70.3 million aggregate principal amount of the 3.50% Convertible Notes with approximately $70.3 million aggregate principal amount of the 3.50% Series A Convertible Notes. Pursuant to the note exchange agreements, the Company also paid the Participating Holders an aggregate of approximately $0.4 million in cash in connection with such transactions. The principal amount of 3.50% Convertible Notes refinanced for each $1,000 principal amount of the 3.50% Series A Convertible Notes was $1,000 and the amount in cash paid per $1,000 principal amount of such 3.50% Convertible Notes delivered was determined in individual negotiations between the Company and each Participating Holder. The Series A Convertible Notes have the same interest rate, maturity and other terms as the 3.50% Convertible Notes, except that the 3.50% Series A Convertible Notes are convertible into cash, shares of the Company's common stock or a combination of cash and shares of common stock, at the Company's option.
	The 3.50% Series A Convertible Notes were issued under an Indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Holders of the 3.50% Series A Convertible Notes may convert their Securities at any time on or after November 1, 2017 until the close of business on the business day immediately preceding the maturity date. Prior to November 1, 2017, holders of the 3.50% Series A Convertible Notes may convert their Securities only under the following circumstances: (1) during any calendar quarter after the calendar quarter ending September 30, 2014, and only during such calendar quarter, if the closing sale price of the Company's common stock for each of 20 or more trading days in the 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter exceeds 130% of the conversion price in effect on the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading-day period (such five consecutive trading-day period, the "Note Measurement Period") in which the trading price per $1,000 principal amount of 3.50% Series A Convertible Notes for each trading day of that Securities Measurement Period was equal to or less than 98% of the product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day; or (3) upon the occurrence of specified corporate transactions as described in the Indenture. Upon conversion by holders of the 3.50% Series A Convertible Notes, the Company will have the right to pay or deliver, as the case may be, cash, shares of common stock of the Company or a combination thereof, at the Company's election. At any time on or prior to the 17th business day immediately preceding the maturity date, the Company may irrevocably elect to (a) deliver solely shares of common stock of the Company in respect of the Company's conversion obligation or (b) pay cash up to the aggregate principal amount of the 3.50% Series A Convertible Notes to be converted and pay or deliver, as the case may be, cash, shares of common stock of the Company or a combination thereof in respect of the remainder, if any, of the Company's conversion obligation in excess of the aggregate principal amount of the 3.50% Series A Convertible Notes being converted. The initial conversion rate is 187.6877 shares of the Company's common stock per $1,000 principal amount of 3.50% Series A Convertible Notes (which represents an initial conversion price of approximately $5.33 per share of the Company's common stock). The conversion rate, and thus the conversion price, are subject to adjustment as further described below.
	Holders of the 3.50% Series A Convertible Notes who convert their Notes in connection with a "make-whole fundamental change", as defined in the Indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a "fundamental change," as defined in the Indenture, holders of the 3.50% Series A Convertible Notes may require the Company to purchase all or a portion of their 3.50% Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 3.50% Series A Convertible Notes, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date.
	In accordance with Accounting Standards Codification, or ASC 470-20, Debt with Conversion and Other Options, the Company separately accounts for the liability and equity conversion components of the 3.50% Series A Convertible Notes. The principal amount of the liability component of the 3.50% Series A Convertible Notes was $62.5 million as of the date of issuance based on the present value of its cash flows using a discount rate of 7%, our approximate borrowing rate at the date of the issuance for a similar debt instrument without the conversion feature. The carrying value of the equity conversion component was $7.9 million. In addition, the portion of the cash amount paid to the Participating Holders totaling $370 thousand was allocated to the debt discount with the remaining $47 thousand to equity component. The liability component is being accreted to the principal amount of the 3.50% Series A Convertible Notes using the effective interest method through the maturity in February 2018.
	The following table presents the carrying values of all Convertible Notes as of June 30, 2014 (in thousands):
		3.75% Notes			3.50% Notes		3.50% Series A			TOTAL
							Notes
	Carrying amount of the equity conversion component	$	23,189		$	—	$	7,844		$	31,033
	Principal amount of the Convertible Notes	$	100,000		$	44,654	$	70,346		$	215,000
	Unamortized debt discount		(11,489	)		—		(7,899	)		(19,388	)
	Net carrying amount	$	88,511		$	44,654	$	62,447		$	195,612
	As of June 30, 2014, the remaining period over which the unamortized debt discount of the 3.75% Convertible Notes will be amortized is 25 months using an effective interest rate of 10.9%; the remaining amortization period of the 3.50% Series A Convertible Notes is 43 months using an effective interest rate of 7.10%.
	A summary of interest expense on all Convertible Notes is as follows (in thousands):
		Year ended June 30,
		2014			2013		2012
	Interest expense related to contractual interest coupon	$	7,774		$	5,292	$	3,438
	Interest expense related to amortization of debt discount		5,105			4,302		3,596
	Interest expense related to amortization of debt issuance costs		1,408			784		363
		$	14,287		$	10,378	$	7,397

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Jun. 30, 2014
Employee Benefit Plans	'
Employee Benefit Plans	'
	14. Employee Benefit Plans
	The Company's employee savings and retirement plan is qualified under Section 401(k) of the United States Internal Revenue Code. Employees may make voluntary, tax-deferred contributions to the 401(k) Plan up to the statutorily prescribed annual limit. The Company makes discretionary matching contributions to the 401(k) Plan on behalf of employees up to the limit determined by the Board of Directors. The Company contributed $2.1 million, $2.3 million and $2.2 million to the 401(k) Plan during the years ended June 30, 2014, 2013 and 2012, respectively.

Defined_Benefit_Pension_Obliga

Defined Benefit Pension Obligation	12 Months Ended
	Jun. 30, 2014
Defined Benefit Pension Obligation	'
Defined Benefit Pension Obligation	'
	15. Defined Benefit Pension Obligation
	The Company has established a defined pension plan for its employees in Switzerland subsidiary. The plan provides benefits to employees upon retirement, death or disability. The Company uses June 30 as the year-end measurement date for this plan. The unfunded liability of $1.0 million was recognized in long-term other liabilities in the accompanying balance sheet as of June 30, 2014. Actuarial loss of $0.6 million was recognized in other comprehensive income (loss) in fiscal 2014.

Restructuring_Charges

Restructuring Charges	12 Months Ended
	Jun. 30, 2014
Restructuring Charges	'
Restructuring Charges	'
	16. Restructuring Charges
	Fiscal 2013 Restructuring
	During fiscal 2013, the Company initiated a number of restructuring activities to address various areas of its business, including changes in the executive management team and increased focus on improving its commercial execution, revenue growth and profitability. In the year ended June 30, 2013, the Company recorded restructuring charges of $9.1 million, included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Restructuring expenses during the year ended June 30, 2013 were comprised of the following:
	•
	Lease termination charge of $1.4 million, net of estimated sub-lease income, for the remaining lease obligations on an office facility that the Company vacated, and a charge of $0.3 million related to the disposition of certain fixed assets and the write-down of leasehold improvements at this office facility.
	•
	Severance-related charges of $7.4 million primarily related to the terminations of the Company's former Chief Executive Officer and Chief Operating Officer and a 13% reduction in its worldwide headcount.
	Fiscal 2012 Restructuring
	In fiscal 2012, the Company initiated a restructuring plan to reposition its workforce to appropriately support its growth strategy and to help achieve cost synergies associated with its acquisition of TomoTherapy. In connection with this restructuring plan, the Company eliminated approximately 51 full-time positions worldwide, across various functions, and recorded an associated restructuring charge of approximately $1.7 million, primarily comprised of severance and related benefits.
	For the year ended June 30, 2012, the Company recorded total restructuring charges of $1.9 million, including the $1.7 million of restructuring expenses discussed above.

Quarterly_Financial_Data_unaud

Quarterly Financial Data (unaudited)	12 Months Ended
	Jun. 30, 2014
Quarterly Financial Data (unaudited)	'
Quarterly Financial Data (unaudited)	'
	17. Quarterly Financial Data (unaudited)
	The following table provides the selected quarterly financial data for fiscal 2014 and 2013 (in thousands, except per share amounts):
		Quarters ended
		September 30,			December 31,			March 31,			June 30,
		2013			2013			2014			2014
	Net revenue	$	76,641		$	93,634		$	97,144		$	102,000
	Gross profit	$	26,478		$	38,171		$	39,704		$	38,447
	Net loss	$	(15,533	)	$	(5,441	)	$	(4,665	)	$	(9,809	)
	Net earnings per share—basic and diluted	$	(0.21	)	$	(0.07	)	$	(0.06	)	$	(0.13	)
	Shares used in basic and diluted per share calculation		74,700			75,280			76,382			76,879
		Quarters ended
		September 30,			December 31,			March 31,			June 30,
		2012			2012			2013			2013
	Net revenue	$	82,748		$	77,779		$	70,547		$	84,900
	Gross profit	$	23,676		$	26,626		$	20,053		$	27,285
	Loss from continuing operations	$	(21,930	)	$	(25,513	)	$	(31,203	)	$	(18,715	)
	Loss from discontinued operations	$	(2,200	)	$	(3,658	)	$	—		$	—
	Net loss	$	(24,130	)	$	(29,171	)	$	(31,203	)	$	(18,715	)
	Net earnings per share—basic and diluted—continuing operations	$	(0.31	)	$	(0.35	)	$	(0.42	)	$	(0.25	)
	Net earnings per share—basic and diluted—discontinued operations	$	(0.03	)	$	(0.05	)	$	—		$	—
	Net earnings per share—basic and diluted—net loss	$	(0.34	)	$	(0.40	)	$	(0.42	)	$	(0.25	)
	Shares used in basic and diluted per share calculation		71,995			72,870			74,016			74,270

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies	'
Basis of Presentation and Principles of Consolidation	'
	Basis of Presentation and Principles of Consolidation
	The accompanying consolidated financial statements have been prepared in accordance with GAAP, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. The consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries and a variable interest entity, Compact Particle Acceleration Corporation, or CPAC until the deconsolidation of CPAC on December 21, 2012 (for further information, see Note 7, Investment in CPAC). All significant inter-company transactions and balances have been eliminated in consolidation.
Discontinued Operations	'
	Discontinued Operations
	As a result of the deconsolidation of CPAC, the results of operations of CPAC, including the loss on deconsolidation of CPAC and the losses attributable to the non-controlling interest recorded for the years ended June 30, 2013 and 2012 have been presented as discontinued operations.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures at the date of the financial statements. Key estimates and assumptions made by the Company relate to revenue recognition, business combinations and assessment of recoverability of goodwill and intangible assets, valuation of inventories, share-based compensation expense, convertible notes, income taxes, allowance for doubtful accounts and loss contingencies. Actual results could differ materially from those estimates.
Foreign Currency	'
	Foreign Currency
	The Company's international subsidiaries use their local currencies as their functional currencies. For those subsidiaries, assets and liabilities are translated at exchange rates in effect at the balance sheet date and income and expense accounts at the average exchange rate. Resulting translation adjustments are excluded from the determination of net income (loss) and are recorded in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Net foreign currency exchange transaction gains or losses are included as a component of other income (expense), net, in the Company's consolidated statements of operations and comprehensive loss.
Fair Value Measurements	'
	Fair Value Measurements
	The carrying values of the Company's financial instruments including cash equivalents, restricted cash, accounts receivable and accounts payable are approximately equal to their respective fair values due to the relatively short-term nature of these instruments. Also refer to Note 4, Financial Instruments, for further details.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are held in various financial institutions in the United States and internationally.
Investments	'
	Investments
	The Company classifies all its investments as available-for-sale at the time of purchase since it is management's intent that these investments be available for current operations, and as such, includes these investments as short-term investments on its balance sheets. These investments consist of fixed-term deposits, commercial paper and investment-grade corporate debt securities with original maturities longer than three months. Short-term investments classified as available-for-sale are recorded at fair market value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders' equity. Realized gains and losses are recorded in the consolidated statements of operations and comprehensive loss based on specific identification.
Concentration of Credit Risk and Other Risks and Uncertainties	'
	Concentration of Credit Risk and Other Risks and Uncertainties
	The Company's cash and cash equivalents are mainly deposited with several major financial institutions. At times, deposits in these institutions exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances. The Company has placed its investments with high-credit quality issuers. The Company does not invest an amount exceeding 5% of its combined cash, cash equivalents and investments in the securities of any one obligor or maker, except for obligations of the United States government, obligations of United States government agencies and money market accounts.
	There were no customers that represented 10% or more of total net revenue for the years ended June 30, 2014, 2013 and 2012. At June 30, 2014, one customer accounted for 13% of accounts receivable. At June 30, 2013, one customer accounted for 10% of accounts receivable.
	Accounts receivable are typically not collateralized. The Company performs ongoing credit evaluations of its customers and maintains reserves for potential credit losses. Accounts receivable are deemed past due in accordance with the contractual terms of the agreement. Accounts are charged against the allowance for doubtful accounts once collection efforts are unsuccessful. Historically, such losses have been within management's expectations.
	Single-source suppliers presently provide the Company with several components. In most cases, if a supplier was unable to deliver these components, the Company believes that it would be able to find other sources for these components subject to any regulatory qualifications, if required.
Restricted Cash	'
	Restricted Cash
	Restricted cash primarily consists of certificates of deposit held as guarantees in connection with corporate leases as well as funds held as guarantees for Value-Added Tax, or VAT obligations in a foreign jurisdiction.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost (on a first-in, first-out basis) or market value. Excess and obsolete inventories are written down based on historical sales and forecasted demand, as judged by management. The Company determines inventory and product costs, which include allocated production overheads, through use of standard costs, which approximate actual costs.
Revenue Recognition	'
	Revenue Recognition
	The Company's revenue is primarily derived from sales of CyberKnife and TomoTherapy Systems and services, which include post-contract customer support or PCS, installation services, training and other professional services. The Company records its revenues net of any value added or sales tax. In all sales arrangements, the Company recognizes revenues when there is persuasive evidence of an arrangement, the fee is fixed or determinable, collection of the fee is reasonably assured and delivery has occurred. Payments received in advance of system shipment are recorded as customer advances and are recognized as revenue or deferred revenue upon product shipment or installation. The Company assesses the probability of collection based on a number of factors, including past transaction history with the customer and the credit-worthiness of the customer. The Company generally does not request collateral from its customers. If the Company determines that collection is not probable, the Company will defer the fee and recognize revenue upon receipt of cash.
	The Company frequently enters into sales arrangements that contain multiple elements or deliverables. For sale arrangements that contain multiple elements, the Company allocates the arrangement consideration to each element based on the relative selling price method, whereby the relative selling price of each deliverable is determined using vendor specific objective evidence, or VSOE of fair value, if it exists. VSOE of fair value for each element is based on the Company's standard rates charged for the product or service when such product or service is sold separately or based upon the price established by the Company's pricing committee when that product or service is not yet being sold separately. When the Company is not able to establish VSOE for all deliverables in an arrangement with multiple elements, which may be due to the Company infrequently selling each element separately, not pricing products within a narrow range, or only having a limited sales history, the Company attempts to determine the selling price of each element based on third-party evidence of selling price, or TPE, as determined based on competitors' prices for similar deliverables when sold separately. When the Company is not able to establish selling price using VSOE or TPE, the Company uses its best estimate of selling price, or BESP, in its allocation of arrangement consideration. The objective of BESP is to determine the price at which the Company would transact a sale if the product or service were sold on a stand-alone basis. The Company determines BESP for a product or service by considering multiple factors including, but not limited to, pricing practices, internal costs, geographies and gross margin. The determination of BESP is made through consultation with the Company's pricing committee, taking into consideration its overall go-to-market pricing strategy.
	The Company has a limited number of software offerings which are not required to deliver its systems' essential functionality and can be sold separately. The Company accounts for the separate sale of its software products in accordance with the applicable guidance for software revenue recognition. The Company's multiple-element arrangements may also include software deliverables that are subject to the software revenue recognition guidance; and in these cases, the revenue for these multiple-element arrangements is allocated to the software deliverable and the non-software deliverables based on the relative selling prices of all of the deliverables in the arrangement using VSOE, TPE or BESP.
	The Company regularly reviews VSOE, TPE and BESP for all of its products and services. As the Company's go-to-market strategies and other factors change, the Company may modify its pricing practices in the future, which may impact the selling prices of systems and services as well as VSOE, TPE and BESP of systems and services. As a result, the Company's future revenue recognition for multiple element arrangements could differ materially from that recorded in the current period.
	Product Revenue
	The majority of product revenue is generated from sales of CyberKnife and TomoTherapy systems. If the Company is responsible for installation, the Company recognizes revenue after installation and acceptance of the system. Otherwise, revenue is recognized upon delivery, assuming all other revenue recognition criteria are met.
	The Company could sell its systems with PCS contracts, installation services, training, and at times, professional services. PCS contracts provide planned and corrective maintenance services, software updates, bug fixes, as well as call-center support.
	The Company records revenues from sales of systems, product upgrades and accessories to distributors depending on the terms of the distribution agreement as well as terms and conditions executed for each sale, and once all revenue recognition criteria have been met.
	The Company's agreements with customers and distributors for system sales generally do not contain product return rights. Certain distributor agreements include parts inventory buy-back provisions upon distributorship termination. The Company accrues an inventory buy-back liability when and if such distributorship termination is expected and the liability can be estimated.
	Service Revenue
	Service revenue is generated primarily from PCS (warranty period services and post warranty services), installation services, training, and professional services. PCS revenue is deferred and recognized over the service period. Installation service revenue is recognized concurrent with system revenue. Training revenues are recognized when services are performed, and professional service revenues that are not deemed essential to the functionality of the systems are recognized as such services are performed.
	Costs associated with service revenue are expensed when incurred, except when those costs are related to system upgrades where revenue recognition has been deferred. In those cases, the incremental costs are deferred and are recognized over the period of revenue recognition.
Deferred Revenue and Deferred Cost of Revenue	'
	Deferred Revenue and Deferred Cost of Revenue
	Deferred revenue consists of deferred product revenue and deferred service revenue. Deferred product revenue arises from timing differences between the shipment of product and satisfaction of all revenue recognition criteria consistent with the Company's revenue recognition policy. Deferred service revenue results from the advance payment for services to be delivered over a period of time, usually one year. Deferred cost of revenue consists of the direct costs associated with the manufacturing of units and direct service costs for which the revenue has been deferred in accordance with the Company's revenue recognition policies. Deferred revenue and associated deferred cost of revenue expected to be realized within one year are classified as current liabilities and current assets, respectively.
Customer Advances	'
	Customer Advances
	Customer advances represent payments made by customers in advance of product shipment.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are depreciated on a straight-line basis over the remaining term of the lease or the estimated useful life of the asset, whichever is shorter. Machinery and equipment are depreciated over five years. Furniture and fixtures are depreciated over four years. Computer and office equipment and computer software are depreciated over three years. Repairs and maintenance costs, which are not considered improvements and do not extend the useful life of the property and equipment, are expensed as incurred.
Software Capitalization Costs	'
	Software Capitalization Costs
	The Company capitalizes certain costs associated with obtaining or developing internal use software, including external direct costs of material and services. Software development costs relating to assets to be sold in the normal course of business are included in research and development and are expensed as incurred until technological feasibility is established. After technological feasibility is established, material software development costs are capitalized. The capitalized cost is then amortized on a straight-line basis over the estimated product life, or on the ratio of current revenues to total projected product revenue, whichever is greater. To date, the period between achieving technological feasibility, which the Company has defined as the establishment of a working model which typically occurs when the beta testing commences, and the general availability of such software has been short and software development costs qualifying for capitalization have been insignificant.
	Capitalized software costs are included in property, plant and equipment and amortized beginning when the software project is complete and the assets is ready for its intended use.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company reviews long-lived assets, including intangible assets, property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable using pretax undiscounted cash flows. Impairment, if any, is measured as the amount by which the carrying value of a long-lived asset exceeds its fair value.
Business Combinations	'
	Business Combinations
	The Company allocates the fair value of the purchase consideration of its acquisitions to the tangible assets, liabilities, and intangible assets acquired, including in-process research and development, or IPR&D, based on their estimated fair values. Goodwill represents the excess of acquisition cost over the fair value of tangible and identified intangible net assets of businesses acquired. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired company are reflected in the Company's consolidated financial statements after the closing date of the merger or acquisition.
Goodwill and Purchased Intangible Assets	'
	Goodwill and Purchased Intangible Assets
	Goodwill is not amortized, but is evaluated for impairment on an annual basis and when impairment indicators are present. The Company has assessed that it has one operating segment and one reporting unit, and the consolidated net assets, including existing goodwill and other intangible assets, are considered to be the carrying value of the reporting unit. The Company estimates the fair value of the reporting unit based on the Company's closing stock price on the trading day closest to the annual review date multiplied by the outstanding shares on that date. If the carrying value of the reporting unit is in excess of its fair value, an impairment may exist, and the Company must perform the second step of the analysis, in which the implied fair value of the goodwill is compared to its carrying value to determine the impairment charge, if any. If the estimated fair value of the reporting unit exceeds the carrying value of the reporting unit, goodwill is not impaired and no further analysis is required. There was no impairment of goodwill identified in the fiscal years ended June 30, 2014, 2013 and 2012.
	Purchased intangible assets other than goodwill, including developed technology, backlog and distributor license, are amortized on a straight-line basis over their estimated useful lives unless their lives are determined to be indefinite. Purchased intangible assets are carried at cost, less accumulated amortization. Amortization is computed over the estimated useful lives of the respective assets which range from approximately one to six years.
	Acquisition-related expenses and restructuring costs are recognized separately from the business combination and are expensed as incurred.
Shipping and Handling	'
	Shipping and Handling
	The Company's billings for shipping and handling for product shipments to customers are included in cost of products. Shipping and handling costs incurred for inventory purchases are capitalized in inventory and expensed in cost of products.
Advertising Expenses	'
	Advertising Expenses
	The Company expenses the costs of advertising and promoting its products and services as incurred. Advertising expenses were approximately $0.6 million, $0.7 million and $0.5 million for the years ended June 30, 2014, 2013 and 2012, respectively.
Research and Development Costs	'
	Research and Development Costs
	Costs related to research, design and development of products are charged to research and development expense as incurred. These costs include direct salaries, benefits, and other headcount related costs for research and development personnel; costs for materials used in research and development activities; costs for outside services and allocated portions of facilities and other corporate costs. The Company has entered into research and clinical study arrangements with selected hospitals, cancer treatment centers, academic institutions and research institutions worldwide. These agreements support the Company's internal research and development capabilities.
Share-Based Compensation	'
	Share-Based Compensation
	The Company issues stock-based compensation awards to employees and directors in the form of stock options, restricted stock units ("RSUs"), performance stock units ("PSUs"), market stock units ("MSUs") and employee stock purchase plan ("ESPP") awards (collectively, "awards").
	The Company measures and recognizes compensation expense for all stock-based awards based on the awards' fair value. Share-based compensation for RSUs and PSUs is measured based on the value of the Company's common stock on the grant date. The Company uses the Monte-Carlo simulation model to estimate the fair value of MSUs. Share-based compensation for employee stock options and ESPP awards are measured on the date of grant using a Black-Scholes option pricing model.
	Awards vest either on a graded schedule or in a lump sum. The Company determines the fair value of each award as a single award and recognizes the expense on a straight-line basis over the service period of the award, which is generally the vesting period. The exercise price of stock options granted is equal to the fair market value of the Company's common stock on the date of grant. Stock options expire ten years from the date of grant.
	Share-based compensation expense for stock options, RSUs, PSUs and the ESPP is based on awards ultimately expected to vest, and the expense is recorded net of estimated forfeitures. The Company recognizes expense for MSUs net of estimated forfeitures and does not adjust the expense for subsequent changes in the expected outcome of the market-based vesting conditions.
Loss Contingencies	'
	Loss Contingencies
	The Company is involved in various lawsuits, claims and proceedings that arise in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. The Company reviews these provisions at least quarterly and adjusts these provisions to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, and updated information.
Net Loss Per Common Share	'
	Net Loss Per Common Share
	Basic and diluted net loss per share is computed by dividing net loss attributable to stockholders by the weighted average number of common shares outstanding during the year.
	A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to stockholders follows (in thousands):
		Years ended June 30,
		2014			2013			2012
	Numerator:
	Loss from operations used in computing loss per share from continuing operations		(35,448	)		(97,361	)		(71,350	)
	Loss from discontinued operations used in computing loss per share from discontinued operations		—			(5,858	)		(692	)
	Net loss used in computing net loss per share		(35,448	)		(103,219	)		(72,042	)
	Denominator:
	Weighted average shares used in computing basic and diluted net loss per share		75,804			73,281			70,887
	The potentially dilutive shares of the Company's common stock resulting from the assumed exercise of outstanding stock options, the vesting of RSUs, MSUs and PSUs, and the purchase of shares under the ESPP, as determined under the treasury stock method, are excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive. The 3.75% Convertible Senior Notes due August 1, 2016 (the "3.75% Convertible Notes"), the 3.50% Convertible Senior Notes due February 1, 2018 (the "3.50% Convertible Notes") and the 3.50% Series A Convertible Notes (the "3.50% Series A Convertible Notes") due February 1, 2018 are included in the calculation of diluted net income per share only if their inclusion is dilutive. For the years ended June 30, 2014, 2013 and 2012, the potentially dilutive shares under the Convertible Notes were excluded from the calculation of diluted net loss per share as their inclusion would have been anti-dilutive. The following table sets forth all potentially dilutive securities excluded from the computation in the table above because their effect would have been anti-dilutive (in thousands):
		As of June 30,
		2014			2013			2012
	Stock options		3,209			4,844			7,873
	RSUs, PSUs and MSUs		3,947			3,387			2,097
	3.75% Convertible Notes		—			—			—
	3.50% Convertible Notes		8,378			21,576			—
	3.50% Series A Convertible Notes		4,985			—			—
			20,519			29,807			9,970
	Outstanding Convertibles Notes—Diluted Share Impact
	The 3.75% Convertible Notes and 3.50% Series A Convertible Notes have an optional physical (share), cash or combination settlement feature and contain certain conditional conversion features. Due to the optional cash settlement feature and management's intent to settle the principal amount thereof in cash, the conversion shares underlying the outstanding principal amount of the 3.75% Convertible Notes and 3.50% Series A Convertible Notes, totaling approximately 10.6 million shares and 13.2 million shares, respectively, were not included in the potentially diluted share count table above. The Company's average stock price did not exceed the conversion price of the 3.75% Convertible Notes as of June 30, 2014, 2013 and 2012. The 5.0 million potentially dilutive shares of the 3.50% Series A Convertible Notes included in the table above represent the premium over the principal amount due to the higher average share price. The number of premium shares included in the Company's diluted share count will vary with fluctuations in the Company's share price. Higher actual share prices result in a greater number of premium shares.
Income Taxes	'
	Income Taxes
	The Company is required to estimate its income taxes in each of the tax jurisdictions in which it operates prior to the completion and filing of tax returns for such periods. This process involves estimating actual current tax expense together with assessing temporary differences in the treatment of items for tax purposes versus financial accounting purposes that may create net deferred tax assets and liabilities. The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of the Company's assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses, research and development credit carryforwards, and other deferred tax assets.
	The Company records a valuation allowance to reduce its deferred tax assets to the amount the Company believes is more likely than not to be realized. Because of the uncertainty of the realization of the deferred tax assets, the Company has recorded a full valuation allowance against its domestic and certain foreign net deferred tax assets.
	The calculation of unrecognized tax benefits involves dealing with uncertainties in the application of complex global tax regulations. Management regularly assesses the Company's tax positions in light of legislative, bilateral tax treaty, regulatory and judicial developments in the countries in which the Company does business. The Company anticipates that except for $0.3 million in uncertain tax positions that may be reduced related to the lapse of various statutes of limitation, there will be no material changes in uncertain tax positions in the next 12 months.
Accumulated Other Comprehensive Income	'
	Accumulated Other Comprehensive Income
	The components of comprehensive loss consist of net loss, unrealized gains and losses on available-for-sale investments, changes in foreign currency exchange rate translation and net changes related to defined benefit pension plan. The unrealized gains and losses on available-for-sale investments, changes in foreign currency exchange rate translation and net changes related to defined benefit pension plan are excluded from earnings and reported as a component of stockholders' equity. The foreign currency translation adjustment results from those subsidiaries not using the United States dollar as their functional currency since the majority of their economic activities are primarily denominated in their applicable local currency. Accordingly, all assets and liabilities related to these operations are translated at the current exchange rates at the end of each period. The resulting cumulative translation adjustments are recorded directly to the accumulated other comprehensive loss account in stockholders' equity. Revenues and expenses are translated at average exchange rates in effect during the period.
	The components of accumulated other comprehensive income in the equity section of the balance sheets are as follows (in thousands):
		June 30,			June 30,
		2014			2013
	Net unrealized gain (loss) on short-term investments	$	18		$	(457	)
	Cumulative foreign currency translation gain		2,364			2,339
	Change in defined benefit pension obligation		(567	)		—
	Accumulated other comprehensive income	$	1,815		$	1,882
Segment Information	'
	Segment Information
	The Company has determined that it operates in only one segment, as it only reports profit and loss information on an aggregate basis to its chief operating decision maker. Revenue by geographic region is based on the shipping addresses of the Company's customers. The following summarizes revenue by geographic region (in thousands):
		Years ended June 30,
		2014			2013			2012
	Americas	$	156,242		$	143,613		$	189,072
	Europe, Middle East, India and Africa		115,396			101,172			110,331
	Asia (excluding Japan and India)		44,533			37,829			64,026
	Japan		53,248			33,360			45,794
	Total	$	369,419		$	315,974		$	409,223
	Information regarding geographic areas in which the Company has long lived tangible assets is as follows (in thousands):
		June 30,			June 30,
		2014			2013
	Americas	$	30,542		$	31,797
	Europe, Middle East, India and Africa		1,665			1,431
	Asia (excluding Japan and India)		444			498
	Japan		1,740			1,007
	Total	$	34,391		$	34,733
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company in its first quarter of fiscal 2018 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09. The Company is currently evaluating the impact of pending adoption of ASU 2014-09 on its consolidated financial statements.
	In July 2013, the Financial Accounting Standards Board ("FASB") issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU No. 2013-11 requires that entities with an unrecognized tax benefit and a net operating loss carryforward or similar tax loss or tax credit carryforward in the same jurisdiction as the uncertain tax position present the unrecognized tax benefit as a reduction of the deferred tax asset for the loss or tax credit carryforward rather than as a liability, when the uncertain tax position would reduce the loss or tax credit carryforward under the tax law, thereby eliminating diversity in practice regarding this presentation issue. This new guidance is effective prospectively for annual reporting periods beginning on or after December 15, 2013, although retrospective application is permitted. The Company is currently assessing the impact of this guidance, if any, on its consolidated financial statements.
	In March 2013, the FASB issued ASU No. 2013-05, Foreign Currency Matters (Topic 830): Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. This new standard is intended to resolve diversity in practice regarding the release into net income of a cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. ASU No. 2013-05 is effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013. The Company is currently reviewing this standard, but it does not anticipate that its adoption will have a material impact on the Company's consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies	'
Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share	'
	A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to stockholders follows (in thousands):
		Years ended June 30,
		2014			2013			2012
	Numerator:
	Loss from operations used in computing loss per share from continuing operations	$	(35,448	)	$	(97,361	)	$	(71,350	)
	Loss from discontinued operations used in computing loss per share from discontinued operations		—		$	(5,858	)	$	(692	)
	Net loss used in computing net loss per share	$	(35,448	)	$	(103,219	)	$	(72,042	)
	Denominator:
	Weighted average shares used in computing basic and diluted net loss per share		75,804			73,281			70,887
Schedule of all potentially dilutive securities excluded from the computation of net loss per share	'
	The following table sets forth all potentially dilutive securities excluded from the computation in the table above because their effect would have been anti-dilutive (in thousands):
		As of June 30,
		2014			2013			2012
	Stock options		3,209			4,844			7,873
	RSUs, PSUs and MSUs		3,947			3,387			2,097
	3.75% Convertible Notes		—			—			—
	3.50% Convertible Notes		8,378			21,576			—
	3.50% Series A Convertible Notes		4,985			—			—
			20,519			29,807			9,970
Schedule of accumulated other comprehensive income in the equity section of the balance sheets	'
	The components of accumulated other comprehensive income in the equity section of the balance sheets are as follows (in thousands):
		June 30,			June 30,
		2014			2013
	Net unrealized gain (loss) on short-term investments	$	18		$	(457	)
	Cumulative foreign currency translation gain		2,364			2,339
	Change in defined benefit pension obligation		(567	)		—
	Accumulated other comprehensive income	$	1,815		$	1,882
Schedule of revenue by geographic region	'
	The following summarizes revenue by geographic region (in thousands):
		Years ended June 30,
		2014			2013			2012
	Americas	$	156,242		$	143,613		$	189,072
	Europe, Middle East, India and Africa		115,396			101,172			110,331
	Asia (excluding Japan and India)		44,533			37,829			64,026
	Japan		53,248			33,360			45,794
	Total	$	369,419		$	315,974		$	409,223
Schedule of geographic areas in which the Company has long lived tangible assets	'
	Information regarding geographic areas in which the Company has long lived tangible assets is as follows (in thousands):
		June 30,			June 30,
		2014			2013
	Americas	$	30,542		$	31,797
	Europe, Middle East, India and Africa		1,665			1,431
	Asia (excluding Japan and India)		444			498
	Japan		1,740			1,007
	Total	$	34,391		$	34,733

Balance_Sheet_Components_Table

Balance Sheet Components (Tables)	12 Months Ended
	Jun. 30, 2014
Balance Sheet Components	'
Summary of cash and cash equivalents	'
	The following is a summary of cash and cash equivalents (in thousands):
		June 30,			June 30,
		2014			2013
	Cash	$	91,797		$	60,082
	Certificates of deposit		—			12,758
	Money market funds		549			473
		$	92,346		$	73,313
Schedule of accounts receivable, net	'
	Accounts receivable, net consisted of the following (in thousands):
		June 30,			June 30,
		2014			2013
	Accounts receivable	$	72,969		$	56,830
	Unbilled fees and services		159			788
			73,128			57,618
	Less: Allowance for doubtful accounts		(976	)		(2,160	)
	Accounts receivable, net	$	72,152		$	55,458
Schedule of inventories	'
	Inventories consisted of the following (in thousands):
		June 30,			June 30,
		2014			2013
	Raw materials	$	37,003		$	33,721
	Work-in-process		17,692			20,564
	Finished goods		33,057			27,307
	Inventories	$	87,752		$	81,592
Schedule of property and equipment, net	'
	Property and equipment consisted of the following (in thousands):
		June 30,			June 30,
		2014			2013
	Furniture and fixtures	$	5,351		$	6,506
	Computer and office equipment		10,540			9,481
	Software		10,736			9,586
	Leasehold improvements		18,991			19,199
	Machinery and equipment		39,465			37,371
	Shared ownership systems		6,265			4,979
	Construction in progress		5,877			3,084
			97,225			90,206
	Less: Accumulated depreciation		(62,834	)		(55,473	)
	Property and equipment, net	$	34,391		$	34,733

Financial_Instruments_Tables

Financial Instruments (Tables)	12 Months Ended
	Jun. 30, 2014
Financial Instruments	'
Summary of amortized cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category for cash, cash equivalents and short-term investments	'
	The following tables summarize the amortized cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category for cash, cash equivalents and short-term investments (in thousands):
		June 30, 2014
									Estimated Market Value
		Amortized		Gross		Gross			Cash and Cash		Short-term
		Cost		Unrealized		Unrealized			Equivalents		Investments
				Gains		Losses
	Cash	$	91,797	$	—	$	—		$	91,797	$	—
	Level 1
	Money market funds		549		—		—			549		—
	Level 2
	Corporate notes		79,535		72		(54	)		—		79,553
	Total	$	171,881	$	72	$	(54	)	$	92,346	$	79,553
		June 30, 2013
									Estimated Market Value
		Amortized		Gross		Gross			Cash and Cash		Short-term
		Cost		Unrealized		Unrealized			Equivalents		Investments
				Gains		Losses
	Cash	$	60,082	$	—	$	—		$	60,082	$	—
	Level 1
	Certificates of deposit		15,365		—		—			12,758		2,607
	Money market funds		473		—		—			473		—
			15,838		—		—			13,231		2,607
	Level 2
	Commercial paper		3,993		—		(1	)		—		3,992
	Corporate notes		94,941		—		(456	)		—		94,485
			98,934		—		(457	)		—		98,477
	Total	$	174,854	$	—	$	(457	)	$	73,313	$	101,084
Schedule of contractual maturities of available-for-sale securities	'
	Contractual maturities of available-for-sale securities at June 30, 2014 were as follows (in thousands):
		June 30, 2014
		Amortized		Fair Value
		Cost
	Due in 1 year or less	$	28,663	$	28,678
	Due in 1 - 2 years		25,049		25,050
	Due in 2 - 3 years		25,823		25,825
		$	79,535	$	79,553
Schedule of carrying values and estimated fair values of long-term debt that are measured on a non-recurring basis	'
	The following table summarizes the carrying values and estimated fair values of the Company's Convertible Notes (in thousands):
		June 30, 2014				June 30, 2013
		Carrying		Fair Value		Carrying			Fair Value
		Value				Value
	3.75% Convertible Notes	$	88,511	$	115,415	$	83,768		$	96,560
	3.50% Convertible Notes		44,654		79,388		115,000			144,302
	3.50% Series A Convertible Notes		62,447		125,065		—			—
	Total	$	195,612	$	319,868	$	198,768		$	240,862

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
	Jun. 30, 2014
Business Combinations	'
Schedule of components of purchase price	'
	The fair value of total purchase consideration paid and payable for 100% of Morphormics' equity interest as of the acquisition date was as follows (in thousands):
	Cash paid and payable	$	5,385
	Fair value of pre-existing investment in Morphormics		662
	Total	$	6,047
Schedule of identifiable net tangible and intangible assets acquired and liabilities assumed in the acquisition	'
	The total purchase price was allocated to the net tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date as follows (in thousands):
	Cash and cash equivalents	$	668
	Accounts receivable		283
	Other current assets		7
	Amortizable intangible assets—developed technology		5,100
	Goodwill		77
	Accrued compensation		(88	)
	Total purchase price	$	6,047

Goodwill_and_Purchased_Intangi1

Goodwill and Purchased Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2014
Goodwill and Purchased Intangible Assets	'
Schedule of goodwill	'
	Goodwill as of June 30, 2014 and 2013 and changes in the carrying amount of goodwill for the respective periods are as follows (in thousands):
		June 30,			June 30,
		2014			2013
	Balance at the beginning of the period	$	59,368		$	59,215
	Addition related to acquisition		—			77
	Currency translation and other adjustments		(1,277	)		76
	Balance at the end of the period	$	58,091		$	59,368
Schedule of intangible assets associated with completed acquisitions	'
	The Company's intangible assets associated with completed acquisitions are as follows (in thousands):
				June 30, 2014								June 30, 2013
		Useful		Gross			Accumulated			Net		Gross		Accumulated			Net
		Lives		Carrying			Amortization			Amount		Carrying		Amortization			Amount
				Amount								Amount
		(in years)
	Developed technology	5 - 6		$	46,747		$	(23,230	)	$	23,517	$	46,747	$	(15,276	)	$	31,471
	Distributor license	1.5 - 2.5			2,037			(2,037	)		—		2,043		(1,618	)		425
				$	48,784		$	(25,267	)	$	23,517	$	48,790	$	(16,894	)	$	31,896
Schedule of estimated future amortization expense of purchased intangible assets	'
	The estimated future amortization expense of purchased intangible assets as of June 30, 2014 is as follows (in thousands):
	Year Ending June 30,	Amount
	2015	$	7,953
	2016		7,953
	2017		7,568
	2018		43
	Thereafter		—
		$	23,517

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2014
Commitments and Contingencies	'
Schedule of future minimum lease payments under non-cancelable operating lease agreements and long-term principal and interest on Convertible Note	'
	Future minimum lease payments under non-cancelable operating lease agreements and long-term principal and interest on the Convertible Notes as of June 30, 2014 are as follows (in thousands):
	Year Ending June 30,	Operating		Long-term
		Leases		Debt(1)
	2015	$	6,427	$	7,775
	2016		8,205		7,775
	2017		8,295		104,338
	2018		7,931		117,348
	2019		4,818		—
	Thereafter		17,969		—
	Total	$	53,645	$	237,236
	-1
	These amounts represent principal and interest cash payments over the contractual life of the debt obligations, including anticipated interest payments that are not recorded on the Company's consolidated balance sheet. Any conversion, redemption or purchase of Convertible Notes would impact cash payments noted in the preceding table.

Stock_Incentive_Plan_and_Emplo1

Stock Incentive Plan and Employee Stock Purchase Plan (Tables)	12 Months Ended
	Jun. 30, 2014
Stock Incentive Plan and Employee Stock Purchase Plan	'
Summary of share-based compensation charges	'
	The following table summarizes the share-based compensation charges included in the Company's consolidated statements of operations and comprehensive loss (in thousands):
		Years ended June 30,
		2014			2013			2012
	Cost of revenue	$	1,912		$	1,498		$	1,672
	Research and development		2,585			1,949			2,340
	Selling and marketing		2,059			1,121			729
	General and administrative		4,757			3,648			3,717
		$	11,313		$	8,216		$	8,458
Schedule of weighted average assumptions used for determining fair value of stock options	'
		Years Ended June 30,
		2013		2012
	Risk-free interest rate	0.87% - 1.15%		0.85% - 1.72%
	Dividend yield	—		—
	Expected life	6.25		6.25
	Expected volatility	52.7% - 63.2%		52.0% - 52.9%
Schedule of option activity	'
	A summary of option activity under the Company's Incentive Plan during the fiscal years is presented below (in thousands, except per share and term amounts):
		Options			Weighted			Weighted			Aggregate
		Outstanding			Average			Average			Intrinsic
					Exercise Price			Remaining			Value
								Contractual			(in thousands)
								Life (In Years)
	Balance at June 30, 2011		8,336		$	7.39			5.13		$	19,131
	Options granted		1,399		$	4.53
	Options exercised		(746	)	$	2.5
	Options forfeited/expired		(1,116	)	$	9.79
	Balance at June 30, 2012		7,873		$	7			5.57		$	12,359
	Options granted		1,250		$	6.54
	Options exercised		(1,515	)	$	2.77
	Options forfeited/expired		(2,764	)	$	8.86
	Balance at June 30, 2013		4,844		$	7.15			6.17		$	2,771
	Options granted		—		$	—
	Options exercised		(1,062	)	$	5.01
	Options forfeited/expired		(573	)	$	9.49
	Balance at June 30, 2014		3,209		$	7.44			5.38		$	8,251
	Vested or Expected to vest at June 30, 2014		3,209		$	7.44			5.38		$	8,251
	Exercisable at June 30, 2014		2,470		$	7.87			4.58		$	6,191
Summary of information about outstanding and exercisable options	'
	The following table summarizes information about outstanding and exercisable options at June 30, 2014 (in thousands, except years and exercise prices):
		Options Outstanding									Options Exercisable
	Exercice Prices	Number			Weighted Average			Weighted			Number			Weighted
		Outstanding			Remaining Contractual			Average			Outstanding			Average
					Life (Years)			Exercise Price						Exercise Price
	$3.50 - 4.01		611			4.73		$	3.81			474		$	3.75
	$4.23 - 5.68		477			4.96			5.2			402			5.28
	$5.74 - 6.28		518			6.97			6.14			326			6.07
	$6.31 - 6.58		397			4.66			6.47			359			6.47
	$6.63 - 6.90		111			5.59			6.67			105			6.67
	$6.96		422			8.15			6.96			174			6.96
	$7.06 - 10.36		359			4.42			8.82			316			9
	$13.05 - 18.40		196			3.14			16			196			16
	$22.70		3			1.86			22.7			3			22.7
	$28.47		115			2.61			28.47			115			28.47
	Total Outstanding		3,209			5.38		$	7.44			2,470		$	7.87
Schedule of activity of RSUs, PSUs and MSUs	'
	Unvested Restricted Stock	Restricted			Performance			Market			Total Number of			Weighted Average
		Stock Units			Stock Units			Stock Units			Shares Underlying			Grant Date Fair
		(000's)			(000's)			(000's)			Stock Awards (000's)			Value Per Share
	Unvested at June 30, 2011		658			—			—			658		$	6.97
	Granted		1,047			954			—			2,001			4.53
	Vested		(302	)		—			—			(302	)		4.47
	Cancelled/Forfeited		(193	)		(66	)		—			(259	)		5.67
	Unvested at June 30, 2012		1,210			888			—			2,098			5.16
	Granted		2,200			36			426			2,662			5.52
	Vested		(526	)		(18	)		—			(544	)		5.18
	Cancelled/Forfeited		(460	)		(350	)		(19	)		(829	)		5.18
	Unvested at June 30, 2013		2,424			556			407			3,387			5.66
	Granted		2,125			70			735			2,930			7.28
	Vested		(888	)		(25	)		—			(913	)		8.7
	Cancelled/Forfeited		(545	)		(576	)		(336	)		(1,457	)		5.44
	Unvested at June 30, 2014		3,116			25			806			3,947		$	6.24
Schedule of weighted average assumptions used for determining fair value of ESPP shares	'
		Years Ended June 30,
		2014		2013		2012
	Risk-free interest rate	0.06% - 0.13%		0.07% - 0.14%		0.05% - 0.12%
	Dividend yield	—		—		—
	Expected life	0.5 - 1.0		0.5		0.5
	Expected volatility	27.5% - 46.5%		40.3% - 53.7%		33.6% - 50.6%

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2014
Income Taxes	'
Schedule of components of loss before provision for income taxes on the accompanying statements of operations and comprehensive loss	'
	Loss before provision for income taxes on the accompanying statements of operations and comprehensive loss included the following components (in thousands):
		Years Ended June 30,
		2014			2013			2012
	Domestic	$	(42,485	)	$	(103,964	)	$	(75,391	)
	Foreign		10,125			10,176			6,636
	Total worldwide	$	(32,360	)	$	(93,788	)	$	(68,755	)
Schedule of provision for income taxes	'
	The provision for income taxes consisted of the following (in thousands):
		Years Ended June 30,
		2014			2013			2012
	Current:
	Federal	$	—		$	—		$	—
	State		78			(21	)		(7	)
	Foreign		2,918			2,647			2,107
	Total current		2,996			2,626			2,100
	Deferred:
	Federal		—			—			—
	State		—			—			—
	Foreign		92			947			495
	Total deferred		92			947			495
	Total provision for income taxes	$	3,088		$	3,573		$	2,595
Schedule of reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes	'
	A reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of operations and comprehensive loss is as follows (in thousands):
		Years Ended June 30,
		2014			2013			2012
	U.S. federal taxes (benefit):
	At federal statutory rate	$	(11,326	)	$	(32,826	)	$	(24,064	)
	State tax, net of federal benefit		78			(21	)		(7	)
	Stock-based compensation expense		332			4,061			3,645
	Change in valuation allowance		13,997			33,454			24,796
	Credits		(114	)		(1,272	)		(846	)
	Other		640			69			(1,245	)
	Foreign taxes		(519	)		108			316
	Total	$	3,088		$	3,573		$	2,595
Schedule of significant components of deferred tax assets	'
	Significant components of the Company's net deferred tax assets were as follows (in thousands):
		June 30,
		2014			2013
	Deferred tax assets:
	Federal and state net operating losses	$	116,734		$	105,110
	Accrued expenses and reserves		6,410			7,021
	Deferred revenue		1,217			1,913
	Credits		16,686			16,636
	Share-based compensation expense		5,391			10,691
	Unicap		1,710			1,540
	Other		904			623
	Total deferred tax assets		149,052			143,534
	Deferred tax liabilities:
	Debt discount		(7,087	)		(4,884	)
	Fixed assets/intangibles		(8,268	)		(11,740	)
	Foreign currency differences		(7	)		(1,697	)
	Total deferred tax liabilities		(15,362	)		(18,321	)
	Valuation allowance		(133,039	)		(124,781	)
	Net deferred tax assets	$	651		$	432
Schedule of aggregate changes in the balance of gross unrecognized tax benefits	'
	The aggregate changes in the balance of gross unrecognized tax benefits were as follows (in thousands):
		Years Ended June 30,
		2014			2013			2012
	Balance at beginning of year	$	16,749		$	15,147		$	14,158
	Tax positions related to current year:
	Additions		1,489			1,781			1,129
	Tax positions related to prior years:
	Additions		—			564			40
	Reductions		(1,069	)		(743	)		(180	)
	Balance at end of year	$	17,169		$	16,749		$	15,147

Other_Income_Expense_Net_Table

Other Income (Expense), Net (Tables)	12 Months Ended
	Jun. 30, 2014
Other Income (Expense), Net	'
Schedule of other income (expense), net	'
	Other income (expense), net consisted of the following (in thousands):
		Years Ended June 30,
		2014			2013			2012
	Interest expense on convertible notes	$	(14,287	)	$	(10,378	)	$	(7,397	)
	Foreign currrency transaction loss		(91	)		(2,503	)		(4,386	)
	Other		162			(252	)		(738	)
	Total other expense, net	$	(14,216	)	$	(13,133	)	$	(12,521	)

Debt_Tables

Debt (Tables)	12 Months Ended
	Jun. 30, 2014
Debt	'
Schedule of carrying value of Convertible Notes	'
	The following table presents the carrying values of all Convertible Notes as of June 30, 2014 (in thousands):
		3.75% Notes			3.50% Notes		3.50% Series A			TOTAL
							Notes
	Carrying amount of the equity conversion component	$	23,189		$	—	$	7,844		$	31,033
	Principal amount of the Convertible Notes	$	100,000		$	44,654	$	70,346		$	215,000
	Unamortized debt discount		(11,489	)		—		(7,899	)		(19,388	)
	Net carrying amount	$	88,511		$	44,654	$	62,447		$	195,612
Summary of interest expense related to the Convertible Notes	'
	A summary of interest expense on all Convertible Notes is as follows (in thousands):
		Year ended June 30,
		2014			2013		2012
	Interest expense related to contractual interest coupon	$	7,774		$	5,292	$	3,438
	Interest expense related to amortization of debt discount		5,105			4,302		3,596
	Interest expense related to amortization of debt issuance costs		1,408			784		363
		$	14,287		$	10,378	$	7,397

Quarterly_Financial_Data_unaud1

Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Jun. 30, 2014
Quarterly Financial Data (unaudited)	'
Schedule of quarterly financial data (unaudited)	'
	The following table provides the selected quarterly financial data for fiscal 2014 and 2013 (in thousands, except per share amounts):
		Quarters ended
		September 30,			December 31,			March 31,			June 30,
		2013			2013			2014			2014
	Net revenue	$	76,641		$	93,634		$	97,144		$	102,000
	Gross profit	$	26,478		$	38,171		$	39,704		$	38,447
	Net loss	$	(15,533	)	$	(5,441	)	$	(4,665	)	$	(9,809	)
	Net earnings per share—basic and diluted	$	(0.21	)	$	(0.07	)	$	(0.06	)	$	(0.13	)
	Shares used in basic and diluted per share calculation		74,700			75,280			76,382			76,879
		Quarters ended
		September 30,			December 31,			March 31,			June 30,
		2012			2012			2013			2013
	Net revenue	$	82,748		$	77,779		$	70,547		$	84,900
	Gross profit	$	23,676		$	26,626		$	20,053		$	27,285
	Loss from continuing operations	$	(21,930	)	$	(25,513	)	$	(31,203	)	$	(18,715	)
	Loss from discontinued operations	$	(2,200	)	$	(3,658	)	$	—		$	—
	Net loss	$	(24,130	)	$	(29,171	)	$	(31,203	)	$	(18,715	)
	Net earnings per share—basic and diluted—continuing operations	$	(0.31	)	$	(0.35	)	$	(0.42	)	$	(0.25	)
	Net earnings per share—basic and diluted—discontinued operations	$	(0.03	)	$	(0.05	)	$	—		$	—
	Net earnings per share—basic and diluted—net loss	$	(0.34	)	$	(0.40	)	$	(0.42	)	$	(0.25	)
	Shares used in basic and diluted per share calculation		71,995			72,870			74,016			74,270

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
	customer	customer
Cash, cash equivalent and investments | Investment concentration risk	'	'
Concentration of Credit Risk and Other Risks and Uncertainties	'	'
Number of obligors or makers	1	'
Cash, cash equivalent and investments | Investment concentration risk | Maximum	'	'
Concentration of Credit Risk and Other Risks and Uncertainties	'	'
Percentage of concentration risk	5.00%	'
Total accounts receivable | Credit concentration risk | Major customers	'	'
Concentration of Credit Risk and Other Risks and Uncertainties	'	'
Percentage of concentration risk	13.00%	10.00%
Number of significant customers	1	1

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 2)	12 Months Ended
	Jun. 30, 2014
Deferred Revenue and Deferred Cost of Revenue	'
Period over which deferred service revenue resulting from advance payment for services are to be delivered	'1 year
Maximum expected period to classify deferred revenue as current liabilities and deferred costs of revenue as current assets	'1 year

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 3)	12 Months Ended
	Jun. 30, 2014
Machinery and equipment	'
Property and Equipment	'
Period over which property and equipment are depreciated	'5 years
Furniture and fixtures	'
Property and Equipment	'
Period over which property and equipment are depreciated	'4 years
Computer and office equipment	'
Property and Equipment	'
Period over which property and equipment are depreciated	'3 years
Computer software	'
Property and Equipment	'
Period over which property and equipment are depreciated	'3 years

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 4) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
	item
Goodwill and Purchased Intangible Assets	'	'	'
Number of operating segments	1	'	'
Number of reporting units	1	'	'
Impairment of goodwill	$0	$0	$0
Advertising Expenses	'	'	'
Advertising expenses	$0.60	$0.70	$0.50
Minimum	'	'	'
Goodwill and Purchased Intangible Assets	'	'	'
Estimated useful lives of respective assets	'1 year	'	'
Maximum	'	'	'
Goodwill and Purchased Intangible Assets	'	'	'
Estimated useful lives of respective assets	'6 years	'	'

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details 5) (USD $)

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Aug. 02, 2011

Jun. 30, 2014

Jun. 30, 2013

Apr. 30, 2014

Apr. 17, 2014

Feb. 28, 2013

Jun. 30, 2014

Apr. 30, 2014

Apr. 17, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

3.75% Convertible Notes

3.75% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Series A Convertible Notes

3.50% Series A Convertible Notes

3.50% Series A Convertible Notes

Stock options

Stock options

Stock options

RSUs, PSUs and MSUs

RSUs, PSUs and MSUs

RSUs, PSUs and MSUs

Numerator:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss from operations used in computing loss per share from continuing operations

'

'

'

'

($18,715,000)

($31,203,000)

($25,513,000)

($21,930,000)

($35,448,000)

($97,361,000)

($71,350,000)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss from discontinued operations used in computing loss per share from discontinued operations

'

'

'

'

'

'

'

'

'

-5,858,000

-692,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss attributable to stockholders

'

'

'

'

'

'

'

'

-35,448,000

-103,219,000

-72,042,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Denominator:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average shares used in computing basic and diluted net loss per share

76,879,000

76,382,000

75,280,000

74,700,000

74,270,000

74,016,000

72,870,000

71,995,000

75,804,000

73,281,000

70,887,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Anti-dilutive securities excluded from computation of earnings per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiration period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

Anti-dilutive securities excluded from the computation of diluted net loss per share (in shares)

'

'

'

'

'

'

'

'

20,519,000

29,807,000

9,970,000

'

'

8,378,000

21,576,000

'

'

'

4,985,000

'

'

3,209,000

4,844,000

7,873,000

3,947,000

3,387,000

2,097,000

Interest rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

3.75%

3.75%

3.50%

3.50%

3.50%

3.50%

3.50%

3.50%

3.50%

3.50%

'

'

'

'

'

'

Conversion shares outstanding principal amount excluded in the potentially diluted share

'

'

'

'

'

'

'

'

'

'

'

10,600,000

'

'

'

'

'

'

13,200,000

'

'

'

'

'

'

'

'

Income Taxes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction in uncertain tax position due to lapse of various statutes of limitation

'

'

'

'

'

'

'

'

$300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Subsequent period within which no material changes in unrecognized tax benefits are expected

'

'

'

'

'

'

'

'

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_Significant_Account8

Summary of Significant Accounting Policies (Details 6) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Accumulated Other Comprehensive Income	'	'
Net unrealized gain (loss) on short-term investments	$18	($457)
Cumulative foreign currency translation gain	2,364	2,339
Change in defined benefit pension obligation	-567	'
Accumulated other comprehensive income	$1,815	$1,882

Summary_of_Significant_Account9

Summary of Significant Accounting Policies (Details 7) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
									item
Summary of Significant Accounting Policies	'	'	'	'	'	'	'	'	'	'	'
Number of operating segments	'	'	'	'	'	'	'	'	1	'	'
Segment Information	'	'	'	'	'	'	'	'	'	'	'
Revenue	$102,000	$97,144	$93,634	$76,641	$84,900	$70,547	$77,779	$82,748	$369,419	$315,974	$409,223
Long lived assets	34,391	'	'	'	34,733	'	'	'	34,391	34,733	'
Americas	'	'	'	'	'	'	'	'	'	'	'
Segment Information	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	156,242	143,613	189,072
Long lived assets	30,542	'	'	'	31,797	'	'	'	30,542	31,797	'
Europe, Middle East, India and Africa	'	'	'	'	'	'	'	'	'	'	'
Segment Information	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	115,396	101,172	110,331
Long lived assets	1,665	'	'	'	1,431	'	'	'	1,665	1,431	'
Asia (excluding Japan and India)	'	'	'	'	'	'	'	'	'	'	'
Segment Information	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	44,533	37,829	64,026
Long lived assets	444	'	'	'	498	'	'	'	444	498	'
Japan	'	'	'	'	'	'	'	'	'	'	'
Segment Information	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	53,248	33,360	45,794
Long lived assets	$1,740	'	'	'	$1,007	'	'	'	$1,740	$1,007	'

Balance_Sheet_Components_Detai

Balance Sheet Components (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Cash and Cash Equivalents	'	'	'	'
Cash	$91,797,000	$60,082,000	'	'
Certificates of deposit	'	12,758,000	'	'
Money market funds	549,000	473,000	'	'
Cash and cash equivalents	92,346,000	73,313,000	143,504,000	95,906,000
Accounts receivable, net	'	'	'	'
Accounts receivable	72,969,000	56,830,000	'	'
Unbilled fees and services	159,000	788,000	'	'
Accounts and other receivable, gross	73,128,000	57,618,000	'	'
Less: Allowance for doubtful accounts	-976,000	-2,160,000	'	'
Accounts receivable, net	72,152,000	55,458,000	'	'
Deduction for allowance for doubtful accounts	700,000	0	'	'
Addition for allowance for doubtful accounts	0	800,000	'	'
Write-offs of allowance for doubtful accounts	500,000	300,000	'	'
Financing receivables	'	'	'	'
Accounts receivable with contractual maturities of more than one year	2,800,000	2,900,000	'	'
Allowance for doubtful financing receivable accounts related to financing receivables	0	0	'	'
Inventories	'	'	'	'
Raw materials	37,003,000	33,721,000	'	'
Work-in-process	17,692,000	20,564,000	'	'
Finished goods	33,057,000	27,307,000	'	'
Total inventories	87,752,000	81,592,000	'	'
Property and Equipment, net	'	'	'	'
Property and equipment, gross	97,225,000	90,206,000	'	'
Less: Accumulated depreciation and amortization	-62,834,000	-55,473,000	'	'
Property and equipment, net	34,391,000	34,733,000	'	'
Depreciation and amortization expense	12,200,000	15,200,000	16,400,000	'
Furniture and fixtures	'	'	'	'
Property and Equipment, net	'	'	'	'
Property and equipment, gross	5,351,000	6,506,000	'	'
Computer and office equipment	'	'	'	'
Property and Equipment, net	'	'	'	'
Property and equipment, gross	10,540,000	9,481,000	'	'
Software	'	'	'	'
Property and Equipment, net	'	'	'	'
Property and equipment, gross	10,736,000	9,586,000	'	'
Leasehold improvements	'	'	'	'
Property and Equipment, net	'	'	'	'
Property and equipment, gross	18,991,000	19,199,000	'	'
Machinery and equipment	'	'	'	'
Property and Equipment, net	'	'	'	'
Property and equipment, gross	39,465,000	37,371,000	'	'
Shared ownership systems	'	'	'	'
Property and Equipment, net	'	'	'	'
Property and equipment, gross	6,265,000	4,979,000	'	'
Construction in progress	'	'	'	'
Property and Equipment, net	'	'	'	'
Property and equipment, gross	$5,877,000	$3,084,000	'	'

Financial_Instruments_Details

Financial Instruments (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Cash, cash equivalents and short-term investments	'	'	'	'
Cash	$91,797	$60,082	'	'
Amortized Cost	79,535	'	'	'
Gross Unrealized Gains	72	'	'	'
Gross Unrealized Losses	-54	-457	'	'
Available-for-sale Securities	79,553	'	'	'
Total Amortized Cost	171,881	174,854	'	'
Cash and Cash Equivalents	92,346	73,313	143,504	95,906
Short-term investments	79,553	101,084	'	'
Other-than-temporary impairments associated with credit losses	0	'	'	'
Amortized Cost	'	'	'	'
Due in 1 year or less	28,663	'	'	'
Due in 1-2 years	25,049	'	'	'
Due in 2-3 years	25,823	'	'	'
Amortized cost	79,535	'	'	'
Fair Value	'	'	'	'
Due in 1 year or less	28,678	'	'	'
Due in 1-2 years	25,050	'	'	'
Due in 2-3 years	25,825	'	'	'
Available-for-sale Securities	79,553	'	'	'
Level 1	'	'	'	'
Cash, cash equivalents and short-term investments	'	'	'	'
Cash Equivalents	'	13,231	'	'
Cash Equivalents and Short-term Investments including Available-for-sale Securities	'	15,838	'	'
Available-for-sale Securities	'	2,607	'	'
Fair Value	'	'	'	'
Available-for-sale Securities	'	2,607	'	'
Level 1 | Certificates of deposits	'	'	'	'
Cash, cash equivalents and short-term investments	'	'	'	'
Cash Equivalents	'	12,758	'	'
Cash Equivalents and Short-term Investments including Available-for-sale Securities	'	15,365	'	'
Available-for-sale Securities	'	2,607	'	'
Fair Value	'	'	'	'
Available-for-sale Securities	'	2,607	'	'
Level 1 | Money market funds	'	'	'	'
Cash, cash equivalents and short-term investments	'	'	'	'
Cash Equivalents	549	473	'	'
Level 2	'	'	'	'
Cash, cash equivalents and short-term investments	'	'	'	'
Amortized Cost	'	98,934	'	'
Gross Unrealized Losses	'	-457	'	'
Available-for-sale Securities	'	98,477	'	'
Amortized Cost	'	'	'	'
Amortized cost	'	98,934	'	'
Fair Value	'	'	'	'
Available-for-sale Securities	'	98,477	'	'
Level 2 | Commercial paper	'	'	'	'
Cash, cash equivalents and short-term investments	'	'	'	'
Amortized Cost	'	3,993	'	'
Gross Unrealized Losses	'	-1	'	'
Available-for-sale Securities	'	3,992	'	'
Amortized Cost	'	'	'	'
Amortized cost	'	3,993	'	'
Fair Value	'	'	'	'
Available-for-sale Securities	'	3,992	'	'
Level 2 | Corporate notes	'	'	'	'
Cash, cash equivalents and short-term investments	'	'	'	'
Amortized Cost	79,535	94,941	'	'
Gross Unrealized Gains	72	'	'	'
Gross Unrealized Losses	-54	-456	'	'
Available-for-sale Securities	79,553	94,485	'	'
Amortized Cost	'	'	'	'
Amortized cost	79,535	94,941	'	'
Fair Value	'	'	'	'
Available-for-sale Securities	$79,553	$94,485	'	'

Financial_Instruments_Details_

Financial Instruments (Details 2) (USD $)

Jun. 30, 2014

Aug. 02, 2011

Jun. 30, 2014

Apr. 30, 2014

Apr. 17, 2014

Jun. 30, 2013

Feb. 28, 2013

Jun. 30, 2014

Apr. 30, 2014

Apr. 17, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

In Thousands, unless otherwise specified

3.75% Convertible Notes

3.75% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Series A Convertible Notes

3.50% Series A Convertible Notes

3.50% Series A Convertible Notes

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Carrying Value

Carrying Value

Carrying Value

Carrying Value

Carrying Value

Carrying Value

Carrying Value

Fair Value

Fair Value

Fair Value

Fair Value

Fair Value

Fair Value

Fair Value

3.75% Convertible Notes

3.75% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Series A Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Series A Convertible Notes

Fair value measurement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long term debt

'

'

'

'

'

'

'

'

'

'

$195,612

$198,768

$88,511

$83,768

$44,654

$115,000

$62,447

$319,868

$240,862

$115,415

$96,560

$79,388

$144,302

$125,065

Interest rate (as a percent)

3.75%

3.75%

3.50%

3.50%

3.50%

3.50%

3.50%

3.50%

3.50%

3.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business_Combinations_Details

Business Combinations (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jul. 16, 2012
In Thousands, unless otherwise specified				Morphormics
Acquisition	'	'	'	'
Acquisition of remaining outstanding shares (as a percent)	'	'	'	90.00%
Outstanding shares held prior to acquisition (as a percent)	'	'	'	10.00%
Fair value of outstanding shares prior to acquisition	'	'	'	$662
Total acquired equity interest (as a percent)	'	'	'	100.00%
Fair value of total purchase consideration paid and payable	'	'	'	'
Cash paid and payable	'	'	'	5,385
Fair value of pre-existing investment in Morphormics	'	'	'	662
Total purchase price	'	'	'	6,047
Purchase price allocation	'	'	'	'
Cash and cash equivalents	'	'	'	668
Accounts receivable	'	'	'	283
Other current assets	'	'	'	7
Amortizable intangible assets - developed technology	'	'	'	5,100
Goodwill	58,091	59,368	59,215	77
Accrued compensation	'	'	'	-88
Total purchase price	'	'	'	$6,047

Goodwill_and_Purchased_Intangi2

Goodwill and Purchased Intangible Assets (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

Sep. 30, 2013

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Minimum

Maximum

TomoTherapy

IPR&D technology carried out by CPAC

Developed technology

Developed technology

Developed technology

Developed technology

Distributor license

Distributor license

Distributor license

Distributor license

Liabilities related to unrecognized tax

Minimum

Maximum

Minimum

Maximum

Changes in the carrying amount of goodwill

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at the beginning of the period

$59,368,000

$59,215,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Addition related to acquisition

'

77,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Currency translation and other adjustment

-1,277,000

76,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at the end of the period

58,091,000

59,368,000

59,215,000

'

'

'

'

'

'

'

'

'

'

'

'

Intangible Assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued liabilities

'

'

'

'

'

1,300,000

'

'

'

'

'

'

'

'

'

Impairment of goodwill

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

Useful Lives

'

'

'

'1 year

'6 years

'

'

'

'

'5 years

'6 years

'

'

'1 year 6 months

'2 years 6 months

Gross Carrying Amount, Finite Lived Intangibles

'

'

'

'

'

'

'

46,747,000

46,747,000

'

'

2,037,000

2,043,000

'

'

Total gross carrying amount

48,784,000

48,790,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated Amortization

-25,267,000

-16,894,000

'

'

'

'

'

-23,230,000

-15,276,000

'

'

-2,037,000

-1,618,000

'

'

Net Amount, Finite Lived Intangibles

23,517,000

31,896,000

'

'

'

'

'

23,517,000

31,471,000

'

'

'

425,000

'

'

Impairment charge recorded due to a decrease in projected future usage of the technology

'

12,200,000

'

'

'

'

12,200,000

'

'

'

'

'

'

'

'

Amortization expense

8,400,000

10,400,000

16,200,000

'

'

'

'

'

'

'

'

'

'

'

'

Estimated future amortization expense of purchased intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015

7,953,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016

7,953,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2017

7,568,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2018

43,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Amount, Finite Lived Intangibles

$23,517,000

$31,896,000

'

'

'

'

'

$23,517,000

$31,471,000

'

'

'

$425,000

'

'

Investment_in_CPAC_Details

Investment in CPAC (Details) (USD $)	12 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012	Sep. 30, 2012
		CPAC	CPAC
Investment in CPAC	'	'	'
Ownership interest (as a percent)	'	'	15.40%
Ownership interest on fully diluted basis (as a percent)	'	'	16.30%
Loss on deconsolidation of a consolidated variable interest entity	$3,442	$3,400	'

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Operating Lease Agreements and Long-term Debt	'	'	'
Rent expense	$6,500,000	$8,700,000	$7,100,000
Future minimum lease payments under non-cancelable operating lease agreements	'	'	'
2015	6,427,000	'	'
2016	8,205,000	'	'
2017	8,295,000	'	'
2018	7,931,000	'	'
2019	4,818,000	'	'
Thereafter	17,969,000	'	'
Total	53,645,000	'	'
Long-term principal and interest on Convertible Note	'	'	'
Liability recorded associated with indemnification agreements	0	'	'
License agreement | WARF (Wisconsin Alumni Research Foundation)	'	'	'
License and Royalty Agreements	'	'	'
Royalty costs	700,000	600,000	1,000,000
Royalty amount accrued	100,000	100,000	'
License agreement | WARF (Wisconsin Alumni Research Foundation) | Minimum	'	'	'
License and Royalty Agreements	'	'	'
Annual commitment amount	300,000	'	'
3.75% Convertible Note and 3.50% Convertible Note	'	'	'
Long-term principal and interest on Convertible Note	'	'	'
2015	7,775,000	'	'
2016	7,775,000	'	'
2017	104,338,000	'	'
2018	117,348,000	'	'
Total	$237,236,000	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies (Details 2) (USD $)	Jun. 30, 2013	Sep. 27, 2013	Jun. 30, 2011	Mar. 31, 2011	21-May-12	Apr. 30, 2011
		Best Medical Trade Secret Litigation	Best Medical Patent Litigation	Best Medical Patent Litigation	Rotary Systems	Rotary Systems
			claim	counts		Minimum
			counts	patent
Contingencies	'	'	'	'	'	'
Estimated loss, low end range	$0	'	'	'	'	'
Estimated loss, high end range	500,000	'	'	'	'	'
Attorney fees and costs receivable	'	500,000	'	'	'	'
Number of counts of alleged willful infringement of patents	'	'	'	2	'	'
Number of patents against which lawsuit is not dismissed	'	'	1	2	'	'
Number of patent claims dismissed	'	'	1	'	'	'
Claim for damages	'	'	'	'	'	$50,000
Period to identify alleged trade secrets with specificity or face dismissal of claim with prejudice	'	'	'	'	'60 days	'

Stockholders_Equity_Details

Stockholders' Equity (Details)	12 Months Ended
	Jun. 30, 2012	Jun. 30, 2014	Jun. 30, 2014	Aug. 02, 2011	Jun. 30, 2014	Apr. 30, 2014	Apr. 17, 2014	Jun. 30, 2013	Feb. 28, 2013
			3.75% Convertible Senior Notes	3.75% Convertible Senior Notes	3.50% Convertible Senior Notes	3.50% Convertible Senior Notes	3.50% Convertible Senior Notes	3.50% Convertible Senior Notes	3.50% Convertible Senior Notes
Stockholders' equity	'	'	'	'	'	'	'	'	'
Number of shares of common stock retired	2,140,018	'	'	'	'	'	'	'	'
Authorized common stock reserved for future issuance (in shares)	'	'	13,200,000	'	21,600,000	'	'	'	'
Interest rate (as a percent)	'	'	3.75%	3.75%	3.50%	3.50%	3.50%	3.50%	3.50%
Number of shares of common stock reserved for issuance under stock incentive plans and employee stock purchase plan	'	13,800,000	'	'	'	'	'	'	'

Stock_Incentive_Plan_and_Emplo2

Stock Incentive Plan and Employee Stock Purchase Plan (Details)	12 Months Ended
	Jun. 30, 2014
Stock Incentive Plan	'
Number of stock incentive plans	2
Stock options	'
Stock Incentive Plan	'
Remaining vesting term	'10 years
2007 Plan | Incentive stock option | Minimum	'
Stock Incentive Plan	'
Exercise price of stock options as a percentage of fair market value on the grant date	100.00%
2007 Plan | Non-qualified stock option | Minimum	'
Stock Incentive Plan	'
Exercise price of stock options as a percentage of fair market value on the grant date	85.00%
2007 Plan | Stock options	'
Stock Incentive Plan	'
Exercise price of stock options as a percentage of fair market value on the grant date	25.00%
Vesting period for first 25% vesting rights	'1 year
Remainder vesting period	'36 months
2007 Plan | RSUs	'
Stock Incentive Plan	'
Percentage of the award vesting at first anniversary	50.00%
Percentage of the award vesting at second anniversary	50.00%
2007 Plan | Time-based RSUs	'
Stock Incentive Plan	'
Annual vesting percentage	25.00%

Stock_Incentive_Plan_and_Emplo3

Stock Incentive Plan and Employee Stock Purchase Plan (Details 2) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Share-based compensation charges	'	'	'
Share-based compensation expense	$11,313,000	$8,216,000	$8,458,000
Capitalized share-based compensation costs	500,000	600,000	400,000
Cost of revenue	'	'	'
Share-based compensation charges	'	'	'
Share-based compensation expense	1,912,000	1,498,000	1,672,000
Research and development	'	'	'
Share-based compensation charges	'	'	'
Share-based compensation expense	2,585,000	1,949,000	2,340,000
Selling and marketing	'	'	'
Share-based compensation charges	'	'	'
Share-based compensation expense	2,059,000	1,121,000	729,000
General and administrative	'	'	'
Share-based compensation charges	'	'	'
Share-based compensation expense	$4,757,000	$3,648,000	$3,717,000

Stock_Incentive_Plan_and_Emplo4

Stock Incentive Plan and Employee Stock Purchase Plan (Details 3) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Additional disclosures	'	'	'	'
Share-based compensation expense	$11,313,000	$8,216,000	$8,458,000	'
Stock options	'	'	'	'
Weighted average assumptions used for determining fair value of options	'	'	'	'
Expected life	'	'6 years 3 months	'6 years 3 months	'
Stock options | Maximum	'	'	'	'
Weighted average assumptions used for determining fair value of options	'	'	'	'
Risk-free interest rate (as a percent)	'	1.15%	1.72%	'
Expected volatility (as a percent)	'	63.20%	52.90%	'
Stock options | Minimum	'	'	'	'
Weighted average assumptions used for determining fair value of options	'	'	'	'
Risk-free interest rate (as a percent)	'	0.87%	0.85%	'
Expected volatility (as a percent)	'	52.70%	52.00%	'
2007 Plan	'	'	'	'
Additional disclosures	'	'	'	'
Fair value of common stock (in dollars per share)	$8.80	'	'	'
2007 Plan | Stock options	'	'	'	'
Options Outstanding	'	'	'	'
Balance at the beginning of the year (in shares)	4,844,000	7,873,000	8,336,000	'
Options granted (in shares)	'	1,250,000	1,399,000	'
Options exercised (in shares)	-1,062,000	-1,515,000	-746,000	'
Options forfeited/expired (in shares)	-573,000	-2,764,000	-1,116,000	'
Balance at the end of the year (in shares)	3,209,000	4,844,000	7,873,000	8,336,000
Vested or Expected to vest at the end of the year (in shares)	3,209,000	'	'	'
Exercisable at the end of the year (in shares)	2,470,000	'	'	'
Weighted Average Exercise Price	'	'	'	'
Balance at the beginning of the year (in dollars per share)	$7.15	$7	$7.39	'
Options granted (in dollars per share)	'	$6.54	$4.53	'
Options exercised (in dollars per share)	$5.01	$2.77	$2.50	'
Options forfeited/expired (in dollars per share)	$9.49	$8.86	$9.79	'
Balance at the end of the year (in dollars per share)	$7.44	$7.15	$7	$7.39
Vested or Expected to vest at the end of the year (in dollars per share)	$7.44	'	'	'
Exercisable at the end of the year (in dollars per share)	$7.87	'	'	'
Weighted Average Remaining Contractual Life (In Years)	'	'	'	'
Balance at the end of the year	'5 years 4 months 17 days	'6 years 2 months 1 day	'5 years 6 months 25 days	'5 years 1 month 17 days
Vested or Expected to vest at the end of the year	'5 years 4 months 17 days	'	'	'
Exercisable at the end of the year	'4 years 6 months 29 days	'	'	'
Aggregate Intrinsic Value (in thousands)	'	'	'	'
Balance at the end of the year	8,251,000	2,771,000	12,359,000	19,131,000
Vested or Expected to vest at the end of the year	8,251,000	'	'	'
Exercisable at the end of the year	6,191,000	'	'	'
Additional disclosures	'	'	'	'
Total intrinsic value of options exercised	3,800,000	4,500,000	'	2,900,000
Share-based compensation expense	1,700,000	2,900,000	3,500,000	'
Realized excess tax benefits related to stock options exercises	0	0	0	'
Unrecognized compensation cost related to unvested stock options, net of estimated forfeitures	$2,200,000	'	'	'
Weighted average period for recognition of compensation costs	'2 years 29 days	'	'	'

Stock_Incentive_Plan_and_Emplo5

Stock Incentive Plan and Employee Stock Purchase Plan (Details 4) (2007 Plan, Stock options, USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014
Options Outstanding	'
Number of Shares Outstanding	3,209
Weighted-Average Remaining Contractual Life	'5 years 4 months 17 days
Weighted-Average Exercise Price (in dollars per share)	$7.44
Options Exercisable	'
Number of Shares Exercisable (in shares)	2,470
Weighted-Average Exercise Price (in dollars per share)	$7.87
$3.50 - 4.01	'
Summary of information about stock options outstanding and exercisable	'
Exercise price, low end of range (in dollars per share)	$3.50
Exercise price, high end of range (in dollars per share)	$4.01
Options Outstanding	'
Number of Shares Outstanding	611
Weighted-Average Remaining Contractual Life	'4 years 8 months 23 days
Weighted-Average Exercise Price (in dollars per share)	$3.81
Options Exercisable	'
Number of Shares Exercisable (in shares)	474
Weighted-Average Exercise Price (in dollars per share)	$3.75
$4.23 - 5.68	'
Summary of information about stock options outstanding and exercisable	'
Exercise price, low end of range (in dollars per share)	$4.23
Exercise price, high end of range (in dollars per share)	$5.68
Options Outstanding	'
Number of Shares Outstanding	477
Weighted-Average Remaining Contractual Life	'4 years 11 months 16 days
Weighted-Average Exercise Price (in dollars per share)	$5.20
Options Exercisable	'
Number of Shares Exercisable (in shares)	402
Weighted-Average Exercise Price (in dollars per share)	$5.28
$5.74 - 6.28	'
Summary of information about stock options outstanding and exercisable	'
Exercise price, low end of range (in dollars per share)	$5.74
Exercise price, high end of range (in dollars per share)	$6.28
Options Outstanding	'
Number of Shares Outstanding	518
Weighted-Average Remaining Contractual Life	'6 years 11 months 19 days
Weighted-Average Exercise Price (in dollars per share)	$6.14
Options Exercisable	'
Number of Shares Exercisable (in shares)	326
Weighted-Average Exercise Price (in dollars per share)	$6.07
$6.31- 6.58	'
Summary of information about stock options outstanding and exercisable	'
Exercise price, low end of range (in dollars per share)	$6.31
Exercise price, high end of range (in dollars per share)	$6.58
Options Outstanding	'
Number of Shares Outstanding	397
Weighted-Average Remaining Contractual Life	'4 years 7 months 28 days
Weighted-Average Exercise Price (in dollars per share)	$6.47
Options Exercisable	'
Number of Shares Exercisable (in shares)	359
Weighted-Average Exercise Price (in dollars per share)	$6.47
$6.63- 6.90	'
Summary of information about stock options outstanding and exercisable	'
Exercise price, low end of range (in dollars per share)	$6.63
Exercise price, high end of range (in dollars per share)	$6.90
Options Outstanding	'
Number of Shares Outstanding	111
Weighted-Average Remaining Contractual Life	'5 years 7 months 2 days
Weighted-Average Exercise Price (in dollars per share)	$6.67
Options Exercisable	'
Number of Shares Exercisable (in shares)	105
Weighted-Average Exercise Price (in dollars per share)	$6.67
$6.96	'
Options Outstanding	'
Number of Shares Outstanding	422
Weighted-Average Remaining Contractual Life	'8 years 1 month 24 days
Weighted-Average Exercise Price (in dollars per share)	$6.96
Options Exercisable	'
Number of Shares Exercisable (in shares)	174
Weighted-Average Exercise Price (in dollars per share)	$6.96
$7.06- 10.36	'
Summary of information about stock options outstanding and exercisable	'
Exercise price, low end of range (in dollars per share)	$7.06
Exercise price, high end of range (in dollars per share)	$10.36
Options Outstanding	'
Number of Shares Outstanding	359
Weighted-Average Remaining Contractual Life	'4 years 5 months 1 day
Weighted-Average Exercise Price (in dollars per share)	$8.82
Options Exercisable	'
Number of Shares Exercisable (in shares)	316
Weighted-Average Exercise Price (in dollars per share)	$9
$13.05 - 18.40	'
Summary of information about stock options outstanding and exercisable	'
Exercise price, low end of range (in dollars per share)	$13.05
Exercise price, high end of range (in dollars per share)	$18.40
Options Outstanding	'
Number of Shares Outstanding	196
Weighted-Average Remaining Contractual Life	'3 years 1 month 20 days
Weighted-Average Exercise Price (in dollars per share)	$16
Options Exercisable	'
Number of Shares Exercisable (in shares)	196
Weighted-Average Exercise Price (in dollars per share)	$16
$22.70	'
Options Outstanding	'
Number of Shares Outstanding	3
Weighted-Average Remaining Contractual Life	'1 year 10 months 10 days
Weighted-Average Exercise Price (in dollars per share)	$22.70
Options Exercisable	'
Number of Shares Exercisable (in shares)	3
Weighted-Average Exercise Price (in dollars per share)	$22.70
$28.47	'
Options Outstanding	'
Number of Shares Outstanding	115
Weighted-Average Remaining Contractual Life	'2 years 7 months 10 days
Weighted-Average Exercise Price (in dollars per share)	$28.47
Options Exercisable	'
Number of Shares Exercisable (in shares)	115
Weighted-Average Exercise Price (in dollars per share)	$28.47

Stock_Incentive_Plan_and_Emplo6

Stock Incentive Plan and Employee Stock Purchase Plan (Details 5) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Oct. 31, 2012

Jun. 30, 2014

Jun. 30, 2013

Oct. 31, 2012

Performance Stock Units

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

MSU Program

MSU Program

MSU Program

MSU Program

Restricted Stock Units, Performance Stock Units and Market Stock Units

Restricted Stock Units, Performance Stock Units and Market Stock Units

Restricted Stock Units, Performance Stock Units and Market Stock Units

RSUs

RSUs

RSUs

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Performance Stock Units

Performance Stock Units

Performance Stock Units

Market Stock Units

Market Stock Units

Stock options

Stock options

Stock options

Market Stock Units

Market Stock Units

Market Stock Units

Market Stock Units

TomoTherapy

TomoTherapy

item

Maximum

Total Number of Shares Underlying

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at the beginning of the year (in shares)

'

'

'

'

3,387,000

2,098,000

658,000

'

'

'

2,424,000

1,210,000

658,000

'

'

556,000

888,000

'

407,000

'

'

'

'

'

'

'

'

Granted (in shares)

'

'

'

'

2,930,000

2,662,000

2,001,000

'

'

'

2,125,000

2,200,000

1,047,000

'

'

70,000

36,000

954,000

735,000

426,000

'

'

'

'

'

'

'

Vested (in shares)

'

'

'

'

-913,000

-544,000

-302,000

'

'

'

-888,000

-526,000

-302,000

'

'

-25,000

-18,000

'

'

'

'

'

'

'

0

'

'

Cancelled/Forfeited (in shares)

'

'

'

'

-1,457,000

-829,000

-259,000

'

'

'

-545,000

-460,000

-193,000

'

'

-576,000

-350,000

-66,000

-336,000

-19,000

'

'

'

'

-200,000

'

'

Unvested at the end of the year (in shares)

'

'

'

'

3,947,000

3,387,000

2,098,000

'

'

'

3,116,000

2,424,000

1,210,000

'

'

25,000

556,000

888,000

806,000

407,000

'

'

'

'

'

'

'

Weighted Average Grant Date Fair Value Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested at the beginning of the year (in shares)

'

'

'

'

$5.66

$5.16

$6.97

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in dollars per share)

'

'

'

'

$7.28

$5.52

$4.53

$7.32

$5.89

$4.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7.18

$5.39

'

Vested (in dollars per share)

'

'

'

'

$8.70

$5.18

$4.47

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cancelled/Forfeited (in dollars per share)

'

'

'

'

$5.44

$5.18

$5.67

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested at the end of the year (in shares)

'

'

'

'

$6.24

$5.66

$5.16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional disclosures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost

'

'

'

'

$17,200,000

'

'

$14,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,100,000

'

'

Weighted average period for recognition of compensation costs

'

'

'

'

'2 years 5 months 8 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 29 days

'

'

'

'

'

'

Share-based compensation expense

11,313,000

8,216,000

8,458,000

100,000

'

'

'

6,400,000

3,600,000

2,500,000

'

'

'

300,000

1,400,000

'

'

'

'

'

1,700,000

2,900,000

3,500,000

'

1,800,000

300,000

'

Weighted average grant date fair value (in dollars per share)

'

'

'

'

$7.28

$5.52

$4.53

$7.32

$5.89

$4.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7.18

$5.39

'

Aggregate fair market value of units vested

'

'

'

'

'

'

'

$7,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Target number of shares that participating executives may earn (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

150.00%

Number of measurement periods

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

Vested next twelve months (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

Vested in year two (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

Weighted average fair value (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.48

$2.30

'

'

'

'

Stock_Incentive_Plan_and_Emplo7

Stock Incentive Plan and Employee Stock Purchase Plan (Details 6) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Other disclosures	'	'	'
Share-based compensation expense	$11,313,000	$8,216,000	$8,458,000
ESPP	'	'	'
Stock Incentive Plan	'	'	'
Purchase price expressed as percentage of fair market value of common stock	85.00%	'	'
Weighted average assumptions used for determining fair value of options	'	'	'
Expected life	'	'6 months	'6 months
Other disclosures	'	'	'
Share-based compensation expense	1,300,000	1,300,000	1,100,000
Number of awards granted to employees (in shares)	700,000	700,000	'
Weighted average fair value (in dollars per share)	$5.44	$4.89	'
Unrecognized compensation cost	700,000	'	'
Weighted average period for recognition of compensation costs	'7 months 6 days	'	'
ESPP | Maximum	'	'	'
Stock Incentive Plan	'	'	'
Payroll deductions as percentage of salaries	10.00%	'	'
Number of shares per period up to which employees may purchase	2,500	'	'
Value of shares up to which employees may purchase in any calendar year	$25,000	'	'
Weighted average assumptions used for determining fair value of options	'	'	'
Risk-free interest rate (as a percent)	0.13%	0.14%	0.12%
Expected life	'1 year	'	'
Expected volatility (as a percent)	46.50%	53.70%	50.60%
ESPP | Minimum	'	'	'
Weighted average assumptions used for determining fair value of options	'	'	'
Risk-free interest rate (as a percent)	0.06%	0.07%	0.05%
Expected life	'6 months	'	'
Expected volatility (as a percent)	27.50%	40.30%	33.60%

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Components of income (loss) before provision for income taxes	'	'	'
Domestic	($42,485,000)	($103,964,000)	($75,391,000)
Foreign	10,125,000	10,176,000	6,636,000
Loss before provision for income taxes	-32,360,000	-93,788,000	-68,755,000
Current:	'	'	'
State	78,000	-21,000	-7,000
Foreign	2,918,000	2,647,000	2,107,000
Total current	2,996,000	2,626,000	2,100,000
Deferred:	'	'	'
Foreign	92,000	947,000	495,000
Total deferred	92,000	947,000	495,000
Total provision for income taxes	3,088,000	3,573,000	2,595,000
Income tax payable	2,000,000	1,200,000	'
Reconciliation of income taxes at the statutory federal income tax rate to net income taxes	'	'	'
At federal statutory rate	-11,326,000	-32,826,000	-24,064,000
State tax, net of federal benefit	78,000	-21,000	-7,000
Stock-based compensation expense	332,000	4,061,000	3,645,000
Change in valuation allowance	13,997,000	33,454,000	24,796,000
Credits	-114,000	-1,272,000	-846,000
Other	640,000	69,000	-1,245,000
Foreign taxes	-519,000	108,000	316,000
Total provision for income taxes	3,088,000	3,573,000	2,595,000
Deferred tax assets:	'	'	'
Federal and state net operating losses	116,734,000	105,110,000	'
Accrued expenses and reserves	6,410,000	7,021,000	'
Deferred revenue	1,217,000	1,913,000	'
Credits	16,686,000	16,636,000	'
Share-based compensation expense	5,391,000	10,691,000	'
Unicap	1,710,000	1,540,000	'
Other	904,000	623,000	'
Total deferred tax assets	149,052,000	143,534,000	'
Deferred tax liabilities:	'	'	'
Debt discount	-7,087,000	-4,884,000	'
Fixed assets/intangibles	-8,268,000	-11,740,000	'
Foreign currency differences	-7,000	-1,697,000	'
Total deferred tax liabilities	-15,362,000	-18,321,000	'
Valuation allowance	-133,039,000	-124,781,000	'
Net deferred tax assets	651,000	432,000	'
Income tax uncertainties	'	'	'
Cumulative amount of undistributed earnings upon which no U.S. income taxes provided	$14,700,000	'	'

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Operating loss carryforwards	'
Amount expected to be credited to additional paid-in-capital	$3.90
Federal	'
Operating loss carryforwards	'
Net operating loss carryforwards	320.5
State	'
Operating loss carryforwards	'
Net operating loss carryforwards	$166.80

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Valuation allowance	'	'	'
Valuation allowance percentage established for domestic and foreign net deferred tax assets	100.00%	'	'
Aggregate changes in the balance of gross unrecognized tax benefits	'	'	'
Balance at beginning of year	$16,749,000	$15,147,000	$14,158,000
Tax positions related to current year: Additions	1,489,000	1,781,000	1,129,000
Tax positions related to prior years: Additions	'	564,000	40,000
Tax positions related to prior years: Reductions	-1,069,000	-743,000	-180,000
Balance at end of year	17,169,000	16,749,000	15,147,000
Subsequent period within which no material changes in unrecognized tax benefits are expected	'12 months	'	'
Reduction in uncertain tax position due to lapse of various statutes of limitation	300,000	'	'
Uncertain tax benefits that, if realized, would affect the effective tax rate	10,200,000	'	'
Accrued interest and penalties related to uncertain tax positions	700,000	700,000	'
Federal | Research and development	'	'	'
Tax Credits	'	'	'
Tax credits	16,100,000	'	'
State | Research and development	'	'	'
Tax Credits	'	'	'
Tax credits	$15,700,000	'	'

Other_Income_Expense_Net_Detai

Other Income (Expense), Net (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Other Income (Expense), Net	'	'	'
Interest expense on convertible notes	($14,287)	($10,378)	($7,397)
Foreign currency transaction loss	-91	-2,503	-4,386
Other	162	-252	-738
Total other expense, net	($14,216)	($13,133)	($12,521)

Debt_Details

Debt (Details) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Aug. 02, 2011

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Apr. 17, 2014

Feb. 28, 2013

Apr. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Apr. 17, 2014

Jun. 30, 2014

Apr. 30, 2014

3.75% Convertible Note and 3.50% Convertible Note

3.75% Convertible Note and 3.50% Convertible Note

3.75% Convertible Note and 3.50% Convertible Note

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

New Notes

New Notes

New Notes

Minimum

Maximum

Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount of debt issued

'

'

'

'

'

'

$100,000,000

'

'

'

'

$115,000,000

'

'

'

$70,300,000

'

$70,300,000

Interest rate (as a percent)

'

'

'

'

'

'

3.75%

3.75%

'

'

3.50%

3.50%

3.50%

3.50%

3.50%

3.50%

3.50%

3.50%

Conversion rate, amount of debt to be issued per $1000 of principal amount

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

'

'

Payment to the convertible note holders to modify the notes

-417,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-417,000

'

'

Aggregate principal amount of debt refinanced

7,844,000

'

23,189,000

'

'

'

'

'

'

'

70,300,000

'

70,300,000

'

'

'

'

'

Principal amount of the Notes

215,000,000

'

'

'

'

'

75,900,000

100,000,000

'

'

'

'

44,700,000

44,654,000

'

'

70,346,000

'

Proceeds from debt, net of costs

'

'

'

'

'

'

96,100,000

'

'

'

'

110,500,000

'

'

'

'

'

'

Debt issuance costs, amortization period

'

'

'

'

'

'

'5 years

'

'

'

'

'5 years

'

'

'

'

'

'

Conversion rate, number of shares to be issued per $1000 of principal amount (in shares)

'

'

'

'

'

'

'

105.5548

'

'

'

'

'

187.6877

'

'

'

'

Principal amount used for debt instrument conversion ratio

'

'

'

'

'

'

'

1,000

'

'

'

'

'

1,000

'

'

'

'

Conversion price (in dollars per share)

'

'

'

'

'

'

'

$9.47

'

'

'

'

'

$5.33

'

'

'

'

Number of days within 30 consecutive trading days in which the closing price of the entity's common stock must exceed the conversion price for the notes to be convertible into common stock

'

'

'

'

'

'

'

'

'20 days

'

'

'

'

'

'

'

'20 days

'

Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be convertible into common stock

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

'

'30 days

'

Percentage of the closing sales price of the entity's common stock that the conversion price must exceed in order for the notes to be convertible

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

'

'

'

130.00%

'

Number of consecutive business days immediately after any five consecutive trading day period during the note measurement period

'

'

'

'

'

'

'

'5 days

'

'

'

'

'

'

'

'

'5 days

'

Number of consecutive trading days before five consecutive business days during the note measurement period

'

'

'

'

'

'

'

'5 days

'

'

'

'

'

'

'

'

'5 days

'

Percentage of the trading price to the product of the sale price of the entity's common stock and the conversion rate

'

'

'

'

'

'

'

'

'

98.00%

'

'

'

'

'

'

98.00%

'

Number of working days preceding maturity date for delivery of shares or payment of cash

'

'

'

'

'

'

'

'33 days

'

'

'

'

'

'

'

'

'

'

Repurchase price, as percentage of principal amount, if company undergoes change of control

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

100.00%

'

'

'

'

Percentage of the closing sales price of the entity's common stock that the conversion price must exceed in order for the notes to be redeemable

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

'

'

'

'

'

Number of days within 30 consecutive trading days in which the closing price of the entity's common stock must exceed the conversion price for the notes to be redeemable

'

'

'

'

'

'

'

'

'20 days

'

'

'

'

'

'

'

'

'

Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be redeemable

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

'

'

'

Discount rate on liability component (as a percent)

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

7.00%

'

Portion of cash amount paid allocated to debt discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

370,000

'

Portion of cash amount paid allocated to equity component

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

47,000

'

Debt issuance costs and discount allocated to equity conversion component

'

'

'

'

'

'

900,000

'

'

'

'

'

'

'

'

'

'

'

Carrying amount of the equity conversion component

31,033,000

'

'

'

'

'

24,100,000

23,189,000

'

'

'

'

'

'

'

'

7,844,000

'

Unamortized debt discount

-19,388,000

'

'

'

'

'

'

-11,489,000

'

'

'

'

'

'

'

'

-7,899,000

'

Net carrying amount

195,612,000

198,768,000

'

'

'

'

'

88,511,000

'

'

'

'

'

44,654,000

'

'

62,447,000

'

Amortization period

'

'

'

'

'

'

'

'25 months

'

'

'

'

'

'

'

'

'43 months

'

Interest expense related to contractual interest coupon

'

'

'

7,774,000

5,292,000

3,438,000

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense related to amortization of debt discount

'

'

'

5,105,000

4,302,000

3,596,000

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense related to amortization of debt issuance costs

1,408,000

784,000

363,000

1,408,000

784,000

363,000

'

'

'

'

'

'

'

'

'

'

'

'

Total interest expense recognized

$14,287,000

$10,378,000

$7,397,000

$14,287,000

$10,378,000

$7,397,000

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate (as a percent)

'

'

'

'

'

'

'

10.90%

'

'

'

'

'

'

'

'

7.10%

'

Employee_Benefit_Plans_Details

Employee Benefit Plans (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Employee Benefit Plans	'	'	'
Employer's contribution to the 401(k) Plan	$2.10	$2.30	$2.20

Defined_Benefit_Pension_Obliga1

Defined Benefit Pension Obligation (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Defined Benefit Pension Obligation	'
Unfunded liability	$1
Actuarial loss	$0.60

Restructuring_Charges_Details

Restructuring Charges (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2012
Restructuring and Severance Charges	'	'
Restructuring charges	$9.10	$1.90
Office facility	'	'
Restructuring and Severance Charges	'	'
Restructuring charges	1.4	'
Disposition of fixed assets and leasehold improvements	'	'
Restructuring and Severance Charges	'	'
Restructuring charges	0.3	'
Employee severance	'	'
Restructuring and Severance Charges	'	'
Charges for severance and related benefits	$7.40	$1.70
Expected reduction of staffing (as a percent)	13.00%	'
Number of full-time employees reduced	'	51

Quarterly_Financial_Data_unaud2

Quarterly Financial Data (unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Quarterly Financial Data (unaudited)	'	'	'	'	'	'	'	'	'	'	'
Net revenue	$102,000	$97,144	$93,634	$76,641	$84,900	$70,547	$77,779	$82,748	$369,419	$315,974	$409,223
Gross profit	38,447	39,704	38,171	26,478	27,285	20,053	26,626	23,676	142,800	97,640	137,272
Loss from continuing operations	'	'	'	'	-18,715	-31,203	-25,513	-21,930	-35,448	-97,361	-71,350
Loss from discontinued operations	'	'	'	'	'	'	-3,658	-2,200	'	'	'
Net loss	($9,809)	($4,665)	($5,441)	($15,533)	($18,715)	($31,203)	($29,171)	($24,130)	'	'	'
Net earnings per share - basic and diluted - continuing operations (in dollars per share)	'	'	'	'	($0.25)	($0.42)	($0.35)	($0.31)	($0.47)	($1.33)	($1.01)
Net earnings per share - basic and diluted - discontinued operations (in dollars per share)	'	'	'	'	'	'	($0.05)	($0.03)	'	($0.08)	($0.01)
Basic and diluted - net loss (in dollars per share)	($0.13)	($0.06)	($0.07)	($0.21)	($0.25)	($0.42)	($0.40)	($0.34)	($0.47)	($1.41)	($1.02)
Weighted average shares used in computing basic and diluted loss per share	76,879	76,382	75,280	74,700	74,270	74,016	72,870	71,995	75,804	73,281	70,887